Some applications of the present invention relate in general to valve replacement. More specifically, some applications of the present invention relate to prosthetic valves for replacement of a cardiac valve.
Ischemic heart disease causes regurgitation of a heart valve by the combination of ischemic dysfunction of the papillary muscles, and the dilatation of the ventricle that is present in ischemic heart disease, with the subsequent displacement of the papillary muscles and the dilatation of the valve annulus.
Dilation of the annulus of the valve prevents the valve leaflets from fully coapting when the valve is closed. Regurgitation of blood from the ventricle into the atrium results in increased total stroke volume and decreased cardiac output, and ultimate weakening of the ventricle secondary to a volume overload and a pressure overload of the atrium.
For some applications of the invention, a prosthetic valve support is provided for facilitating minimally invasive (e.g., transcatheter and/or transluminal) implantation of a prosthetic valve at a native valve of a subject. The native valve typically has native check valve functionality, i.e., it functions as a check valve. It is understood that a diseased valve has sub-optimal native check valve functionality, however the term “check valve functionality,” as used in the context of the specification and in the claims, when used with respect to a native valve, refers to the native level of check valve functionality of the native valve. The prosthetic valve support is typically couplable to the native valve (e.g., to leaflets thereof) of the subject without eliminating the check valve functionality of the native valve. The prosthetic valve is subsequently implanted at the native valve by coupling the prosthetic valve to the prosthetic valve support, typically by expanding the prosthetic valve within one or more openings defined by the prosthetic valve support. The implantation of the prosthetic valve at the native valve replaces, at least in part, the check valve functionality of the native valve with substitute check valve functionality of the prosthetic valve. The prosthetic valve support comprises tissue-engaging elements, such as clips. Typically, but not necessarily, the prosthetic valve support further comprises (1) an upstream support portion, configured to be placed against an upstream surface of the native valve, and shaped to define one of the openings, and (2) a stabilizing element, shaped to define another of the openings.
For some applications, the prosthetic valve support is configured to be coupled to the native valve (e.g., to leaflets thereof) without eliminating the check valve functionality of the native valve, by allowing (1) the native leaflets to define a single orifice, and (2) the native valve to function as a single check valve (e.g., to function in a manner that is generally similar to the natural (e.g., physiological) function of the native valve). For some applications, the prosthetic valve support is configured to be coupled to the native valve (e.g., to leaflets thereof) without eliminating the check valve functionality by coupling together respective portions of two leaflets, such that (1) the native leaflets define two orifices, and (2) the native valve functions as two (e.g., parallel) check valves.
For some applications, it is hypothesized that the use of a two-component implant (i.e., comprising the prosthetic valve support and a separate prosthetic valve), advantageously facilitates delivery of the prosthetic valve via a catheter narrower than 28 Fr (e.g., by allowing the use of a ‘minimalistic’ prosthetic valve, such as a prosthetic valve with few or no appendages).
For some applications, it is hypothesized that the use of a prosthetic valve support that does not eliminate check valve functionality of the native valve, facilitates the separate delivery of the prosthetic valve support and the prosthetic valve (i.e., a two-stage delivery), and thereby further facilitates the use of a narrow catheter.
For some applications, it is further hypothesized that the use of the prosthetic valve support enhances the check valve functionality of the native valve, and thereby provides both (1) “repair” of the native valve, and (2) an implantation site that is pre-prepared for subsequent implantation of a prosthetic valve at a later date, should such implantation be subsequently considered necessary.
There is therefore provided, in accordance with an application of the present invention, apparatus for use with a prosthetic valve for implantation at a native valve of a subject, the native valve including at least one native leaflet, the apparatus including:
In an application, the at least two clip arms include a first clip arm, configured to be disposed against an upstream surface of the leaflet, and a second clip arm, configured to be disposed against a downstream surface of the leaflet.
In an application, the clip controller is configured to facilitate opening and closing of the clip irrespective of a state of expansion of the prosthetic valve support.
In an application, the at least one clip includes at least a first clip and a second clip, and the second clip is openable and closeable independently of the first clip.
In an application, the at least one clip includes at least a first clip and a second clip, and the first clip is fixedly coupled to the second clip, and is configured to be decoupled from the second clip.
In an application, the at least one clip is configured to be coupled to a single native leaflet of the native valve.
In an application, the at least one clip is configured to be lockable such that the first clip arm is locked with respect to the second clip arm.
In an application:
In an application, the clip is flexibly coupled to the upstream support portion.
In an application, the clip is coupled to the upstream support portion via a flexible connector, the flexible connector having a length from the upstream support portion to the clip, and the length of the flexible connector is variable.
In an application, the upstream support portion is generally flat.
In an application, the inner perimeter defines the opening, such that the opening has a depth and a width, and the width of the opening is more than four times greater than the depth of the opening.
In an application, the upstream support portion has a free inner edge, and the free inner edge defines the inner perimeter.
In an application, the inner perimeter defines an opening that has a diameter, and the upstream support portion has a diameter that is at least 10 percent greater than the diameter of the opening.
In an application, no part of the prosthetic valve support that circumscribes a space that has a perimeter greater than 60 mm has a height of more than 20 mm.
There is further provided, in accordance with an application of the present invention, apparatus for facilitating implantation of a prosthetic valve at a native heart valve of a subject, the native heart valve including a native annulus and a plurality of native leaflets that provide check valve functionality, the apparatus including a prosthetic valve support, the prosthetic valve support:
In an application, the tissue-engaging elements are configured to couple the prosthetic valve support to the native leaflets without eliminating the check valve functionality, by coupling the prosthetic valve support to the native leaflets such that:
In an application, the tissue-engaging elements include at least a first tissue-engaging element and a second tissue-engaging element, and the first tissue-engaging element is transluminally controllable independently of the second tissue-engaging element.
In an application, the tissue-engaging elements are configured to couple the prosthetic valve support to the native leaflets without eliminating the check valve functionality, by coupling the prosthetic valve support to the native leaflets such that:
In an application:
In an application, the apparatus is configured such that the first tissue-engaging element is transluminally, intracorporeally decouplable from the second tissue-engaging element.
In an application, the prosthetic valve support includes an annular upstream support portion:
In an application, the apparatus further includes the prosthetic valve, and the prosthetic valve includes a flexible netting at at least an upstream portion of the prosthetic valve, and the netting is configured to facilitate coupling of the prosthetic valve to the upstream support portion.
In an application, the prosthetic valve support includes one or more flexible connectors, and each tissue-engaging element is flexibly coupled to the upstream support portion by a respective flexible connector.
In an application, each flexible connector has a length, and is configured such that the length is variable while the tissue-engaging elements are coupled to the native leaflets.
In an application, the upstream support portion has a compressed configuration and an expanded configuration, and is configured (1) to be delivered to the native valve in the compressed configuration, and (2) to be expanded into the expanded configuration at the native valve.
In an application, the apparatus further includes one or more coupling leads, and the apparatus is configured such that the expansion of the upstream support portion is controllable using the coupling leads.
In an application, each coupling lead passes around at least a portion of the upstream support portion, and the apparatus is configured such that the upstream support portion is recompressible from the expanded configuration toward the compressed configuration, by pulling on the coupling leads.
In an application, the prosthetic valve support includes a downstream stabilizing element:
In an application, the apparatus further includes the prosthetic valve, and the prosthetic valve includes a valve body and one or more valve-anchoring elements, the valve-anchoring elements being configured to sandwich the downstream stabilizing element between the valve-anchoring elements and the valve body.
In an application, the prosthetic valve support is configured to be coupled to the native leaflets such that no portion of the prosthetic valve support is disposed upstream of the native annulus.
In an application, the tissue-engaging elements include clips, each clip including a plurality of clip arms, including at least a first clip arm and a second clip arm, and configured to couple at least a portion of one of the native leaflets between the first and second clip arms.
In an application, the apparatus further includes a clip controller, configured to be advanced transluminally to the native valve, and each clip includes a clip-controller interface, configured to be reversibly coupled to the clip controller, and to facilitate extracorporeal control of the clips independently of deployment of the prosthetic valve support.
In an application, each clip is configured such that movement of at least a portion of the clip-controller interface by a first distance, changes a distance between a portion of the first clip arm and a portion of the second clip arm by a second distance that is more than 1.5 times greater than the first distance.
In an application, the tissue-engaging elements are configured to suturelessly couple the prosthetic valve support to the native leaflets.
In an application, the prosthetic valve support is configured to be transluminally, intracorporeally, couplable to the prosthetic valve.
There is further provided, in accordance with an application of the present invention, a method for use at a native valve of a subject, the native valve including at least one native leaflet that provides native check valve functionality, the method including:
In an application:
There is further provided, in accordance with an application of the present invention, apparatus for use with a native heart valve of a subject, the apparatus including:
There is further provided, in accordance with an application of the present invention, apparatus for use with a prosthetic valve for implantation at a native valve of a subject, the native valve (1) defining an orifice, (2) including at least one native leaflet, having a native beating, and (3) having a native blood flow regulation functionality, the apparatus including:
For some applications, techniques described herein are practiced in combination with techniques described in one or more of the references cited in the Background section and Cross-references section of the present patent application.
Reference is made to
Typically, each tissue-engaging element 24 comprises a clip 30, which typically comprises a plurality of clip arms 32 (e.g., two clips arms, e.g., a first clip arm 32a and a second clip arm 32b), the clip being configured to be coupled to a leaflet of the native valve. Clip arms 32a and 32b are movable with respect to each other, thereby opening and closing clip 30 (e.g., moving clip 30 between an open state and a closed state thereof), e.g., as shown in
For some applications of the invention, at least one of the clip arms (e.g., clip arm 32b) comprises a tissue-engaging portion 48 that is articulatably coupled to another portion of the clip arm at an articulation point 47, such that, at a given relative angular disposition of clip arms 32a and 32b (e.g., a degree of openness of clip 30), a relative angular disposition of portion 48 with respect to clip arm 32a, may change (e.g., may be changed). For example, for at least some states of clip 30, the relative angular disposition of clip arm 32a and portion 48 may be generally independent of the relative angular disposition of clip arm 32a and the other portion of clip arm 32b. For example, portion 48 may remain parallel with clip arm 32a, irrespective of the angular disposition of clip arms 32a and 32b. It is hypothesized that this configuration facilitates coupling of clip 30 to the leaflet of the native valve, by allowing the clip to maintain contact with both sides of the leaflet, irrespective of dimensions (e.g., thicknesses) of the leaflet to which clip 30 is coupled.
Prosthetic valve support 22 is typically configured to be implanted using minimally-invasive procedures (e.g., percutaneously). Further typically, the prosthetic valve support is configured to be delivered transluminally (e.g., transfemorally). Alternatively, the prosthetic valve support may be configured to be delivered transthoracically (e.g., transapically). Typically, the prosthetic valve support is configured in this way by being compressible (e.g., crimpable) into a delivery configuration, and by being configured to expand (e.g., automatically) upon deployment at the native valve. Typically, tissue-engaging elements 24 (e.g., clips 30) are coupled to the leaflets of the native valve before prosthetic valve support 22 is fully deployed, such as while at least part of the prosthetic valve support remains within a delivery tube (e.g., as shown in
Clips 30 are typically configured to be controllable (i.e., openable and closable) independently of each other, and/or independently of deployment of prosthetic valve support 22 (e.g., irrespective of a state of deployment of the prosthetic valve support, such as irrespective of a state of expansion of an upstream support portion 60 of the prosthetic valve support, described hereinbelow).
Clip 30 typically further comprises a clip-controller interface 34, which is configured to facilitate control (e.g., opening and closing) of the clip from outside the subject (i.e., to facilitate extracorporeal control of the clip), e.g., by a physician. Clip-controller interface 34 is reversibly couplable to a clip controller 36, which is itself extracorporeally controllable, e.g., by extending from outside the subject to the clip-controller interface. Clip 30 is thereby typically transluminally controllable. Typically, clip controller 36 facilitates control of the clip by applying a force to clip-controller interface 34, e.g., by transferring an extracorporeally-applied force to the clip-controller interface. Typically, clip controller 36 is integral with delivery apparatus that is used to deliver support 22 to the native valve (e.g., delivery apparatus 140, described hereinbelow with reference to
Clip-controller interface 34 is typically articulatably coupled to at least clip arm 32b (e.g., at an articulation point 35), and/or comprises one or more articulatably coupled portions (e.g., a first interface portion 34a and a second interface portion 34b). Clips 30 are typically configured such that movement of clip-controller interface 34 by a first distance d1, moves clip arm 32b by a second distance d2 that is typically more than 1.5 times (e.g., more than 2 times, such as more than 4 times) greater than distance d1. That is, a relatively large range of movement of clip arm 32b is provided by a relatively small range of movement of clip-controller interface 34, e.g., clip-controller interface 34, clip arm 32b, and/or the coupling therebetween, acts as a lever. Clip 30 is typically configured such that clip arm 32b can articulate over more than 60 degrees, e.g., more than 100 degrees, such as up to 180 degrees, around articulation point 31, with respect to clip arm 32a.
It is hypothesized that, for some applications, angles of articulation greater than 80 degrees (e.g., greater than 120 degrees, such as up to 180 degrees) facilitate (1) repeated coupling to, and decoupling from, the native leaflets (e.g., multiple attempts to couple to the native leaflets), and (2) retrieval of the clips and/or the entire prosthetic valve support (e.g., into a delivery tube).
Clip-controller interface 34 (e.g., portion 34a thereof) is typically slidably coupled to at least clip arm 32a. That is, moving of clip-controller interface 34 typically includes sliding of the clip-controller interface with respect to clip arm 32a (e.g., by using clip controller 36).
For some applications of the invention, at least one of clip arms 32 comprises or defines grips 38 and/or teeth 40, which are configured to facilitate coupling of clip 30 to a native leaflet of the native valve. Typically, grips 38 are configured to atraumatically grip the leaflet and teeth 40 are configured to grip, fold around, and/or pierce the leaflet. For some applications of the invention, at least a portion of clip arms 32 is covered with a padding (not shown), configured to cushion the contact between the clip arms and the leaflet.
Typically, clip 30 is lockable, such that clip arm 32b is locked (e.g., immobile) with respect to clip arm 32a.
For some applications, and as shown in
For some applications of the invention, and as shown in
As described hereinabove, clip-controller interface 34 is typically reversibly couplable to clip controller 36. Typically, this reversible coupling is facilitated by a projection 42, defined by clip controller 36, which is configured to be disposed within, and removed from, a depression 44, defined by clip-controller interface 34. Further typically, projection 42 is configured (e.g., shape-set) to move out from depression 44, and is prevented from moving out of depression 44 by obstructing element 58. Following the locking of clip 30 by withdrawing obstructing element 58 (
As described hereinabove, clips 30 are typically configured to be controllable (i.e., openable and closable) independently of each other, and/or independently of deployment of prosthetic valve support 22. Clips 30 are further typically lockable and/or decouplable from controller 36 independently of each other, and/or independently of deployment of the prosthetic valve support. It is to be noted that clips 30 are configured to couple the prosthetic valve support to the native leaflets suturelessly.
Referring again to
Upstream support portion 60 typically has shape-memory (e.g., resilient, pseudoelastic and/or superelastic) properties. Typically, frame 62 comprises a shape-memory (e.g., resilient, pseudoelastic and/or superelastic) material, such that upstream support portion 60 is compressible (e.g., crimpable) when a compressive force is applied (e.g., prior to implantation), and re-expandable when the compressive force is removed (e.g., during implantation). Non-limiting examples of materials that frame 62 may comprise, include nickel-titanium (nitinol), stainless steel, nickel cobalt, cobalt chrome, titanium, tantalum, and palladium.
Non-limiting examples of materials that covering 64 may comprise, include polyethylene terephthalate (e.g., polyester), polytetrafluoroethylene (e.g., Teflon, ePTFE), and pericardial tissue. For some applications, covering 64 comprises a fabric. Typically, a thickness of the covering is less than 0.5 mm, such as less than 0.2 mm, e.g., less than 0.1 mm, or less than 0.05 mm.
Upstream support portion 60 is typically compressible (e.g., crimpable; for delivery to the native valve) into a generally cylindrical shape in which inner perimeter 68 defines a downstream end 71 of the cylindrical shape, and outer perimeter 69 defines an upstream end 73 of the cylindrical shape (see
In the expanded configuration thereof, upstream support portion 60 is typically (but not necessarily) generally flat (e.g., laminar, and/or planar). For some applications, in the expanded configuration, upstream support portion 60 assumes a frustoconical shape. Upstream support portion 60 typically has a thickness of less than 5 mm, e.g., less than 2 mm, such as between 0.3 mm and 2 mm. Inner perimeter 68 (and thereby opening 61) thereby typically has a depth d10 (e.g., a height) from an upstream side 59 of the upstream support portion to a downstream side 63 of the upstream support portion. Depth d10 is less than 5 mm, e.g., less than 2 mm, such as between 0.3 mm and 2 mm. Typically, diameter d4 of opening 61 is more than 4 times (e.g., more than 6 times, such as more than 10 times) greater than depth d10. That is, opening 61 is more than 4 times (e.g., more than 6 times, such as more than 10 times) wider than it is deep. Typically, in the expanded configuration, upstream support portion 60 has a total height of less than 10 mm (e.g., less than 5 mm, such as less than 2 mm).
Typically, inner perimeter 68 comprises, or is defined by, a free inner edge of upstream support portion 60. That is, opening 61 resembles a hole cut out of a lamina (e.g., out of a disc). For some applications, inner perimeter 68 comprises, or is defined by, a curved and/or folded inner edge of upstream support portion 60. If the inner perimeter of upstream support portion 60 comprises, or is defined by, a curved or folded edge, then a radius of curvature of the curved or folded edge is typically less than 2.5 mm, such as less than 1 mm. That is, the curve or fold of the edge is generally sharp, such that when viewed from within opening 61, the curved or folded edge looks generally like a free edge.
Prosthetic valve support 22 typically comprises two or more tissue-engaging elements 24 (e.g., clips 30), coupled to inner perimeter 68 of upstream support portion 60. For such applications, the two tissue-engaging elements are typically disposed opposite each other (e.g., at 180 degrees around inner perimeter 68 from each other).
Typically, tissue-engaging elements 24 (e.g., clips 30) are coupled to upstream support portion 60 (e.g., inner perimeter 68 thereof) by a flexible connector 70, which may comprise polyethylene terephthalate (e.g., polyester), polytetrafluoroethylene (e.g., Teflon, ePTFE), a fabric, nitinol, and/or any other suitable material. Thereby, tissue-engaging elements 24 (e.g., clips 30) are typically flexibly coupled to upstream support portion 60, and/or are able to move independently of each other. Connector 70 may be coupled to upstream support portion 60 and tissue-engaging elements 24 using sutures, welding, and/or any other suitable technique known in the art.
Prosthetic valve support 22 typically further comprises a stabilizing element 80, coupled to clips 30 (e.g., to a downstream portion thereof). Typically, stabilizing element 80 forms a ring shape that defines an opening 81 (e.g., an aperture), and is typically inelastic and at least partly flexible. Opening 81 typically, but not necessarily, has a diameter that is generally equal to diameter d4 of opening 61. Non-limiting examples of materials that stabilizing element 80 may comprise include polyethylene terephthalate (e.g., polyester), PTFE (e.g., ePTFE), nylon, cotton, nitinol, stainless steel, nickel cobalt, cobalt chrome, titanium, tantalum and palladium. Typically, and as shown in
Stabilizing element 80 (and thereby opening 81) typically has a depth d11 (e.g., a height from a most upstream part to a most downstream part) of less than 20 mm (e.g., less than 10 mm, e.g., less than 5 mm, such as less than 1 mm). As described hereinabove, inner perimeter 68 of upstream support portion has a depth d10 of less than 5 mm. Typically, in the expanded configuration, no part of prosthetic valve support 22 that circumscribes a space that has a perimeter greater than 60 mm (e.g., as upstream support portion 60 and stabilizing element 80 typically do) has a height of more than 20 mm. For some applications, in the expanded configuration, no part of the support that circumscribes a space that has a perimeter greater than 60 mm has a height of more than 10 mm. For some applications, in the expanded configuration, no part of the support that circumscribes a space that has a perimeter greater than 60 mm has a height of more than 5 mm.
Reference is made to
As described hereinabove, upstream support portion 60 typically comprises an expandable lattice-structure frame 62.
As described hereinabove, prosthetic valve support 22 comprises one or more tissue-engaging elements 24, and typically further comprises upstream support portion 60 and/or stabilizing element 80.
It is to be noted that upstream support portions 90 and 100, and prosthetic valve supports 322 and 422, may be used (e.g., combined) with apparatus and methods described elsewhere herein. For example, the upstream support portion of any of the prosthetic valve supports described herein may be replaced with upstream support portion 90 or upstream support portion 100, resulting in alternative prosthetic valve supports. Furthermore, these resulting prosthetic valve supports, as well as prosthetic valve supports 322 and 422, may be used in combination with other techniques described herein (e.g., with reference to
Reference is made to
Mitral valve 122 is disposed between a left atrium 124 and a left ventricle 126 of the subject, and comprises two leaflets 128. Atrium 124 is upstream of mitral valve 122 and ventricle 126 is downstream of the mitral valve. Prosthetic valve support 22, in a compressed configuration 30 thereof, is advanced transluminally (e.g., transfemorally and/or transseptally) within a delivery tube 130 of delivery apparatus 140, to atrium 124, and between leaflets 128 (
Prosthetic valve support 22 is advanced out of delivery tube 130 and/or the delivery tube is withdrawn from the prosthetic valve support (
Prosthetic valve support 22 is moved upstream (e.g., proximally) so as to envelope leaflets 128 between clip arms 32 of each clip 30, and each clip is closed around a leaflet, thereby coupling each clip to a leaflet, e.g., by clamping the leaflet between the clip arms (
As described hereinabove, clips 30 (and/or other tissue-engaging elements 24) are typically coupled to the leaflets of the native valve before prosthetic valve support 22 is fully deployed. Clips 30 are typically locked (e.g., as described with reference to
Delivery apparatus 140 typically comprises a pushing member 132. Typically, prosthetic valve support 22 (e.g., upstream support portion 60 thereof) is reversibly coupled to pushing member 132, and is exposed from delivery tube 130 by being pushed using the pushing member. Upstream support portion 60 is typically configured (e.g., shape-set) to automatically expand toward its expanded configuration upon being deployed from delivery tube 130. For some applications of the invention, the upstream support portion “pops” open from the configuration shown in
For some applications, and as shown in
For some applications, and as shown in
For some applications, holding members 134 comprise locking elements and/or coupling leads (e.g., coupling wires, e.g., looped around respective portions of the upstream support portion; not shown in
Thereby, when prosthetic valve support 22 is implanted at an atrioventricular valve of the subject (e.g., mitral valve 122 or a tricuspid valve), clips 30 typically move away from each other during ventricular diastole, and toward each other during ventricular systole. For applications in which prosthetic valve support 22 is implanted at a native semilunar valve of the subject (e.g., an aortic valve or a pulmonary valve), clips 30 typically move toward each other during ventricular diastole, and away from each other during ventricular systole.
Subsequently (e.g., immediately subsequently, or after more than a minute, e.g., after more than 2 minutes, e.g., after more than 5 minutes, such as after more than an hour), a prosthetic valve 150 is transluminally delivered, in a compressed configuration thereof (e.g., within a delivery tube 160), to the native valve, and implanted at the native valve by coupling the prosthetic valve to prosthetic valve support 22. Implantation of prosthetic valve 150 replaces check valve functionality of the native valve with a substitute check valve functionality of the prosthetic valve. The substitute check valve functionality is provided by one or more prosthetic check valve elements (e.g., valve members, such as leaflets, a ball, or a disc), such as those known in the art, which the prosthetic valve comprises (not shown).
Typically, and as shown in
Typically, diameter d3 of upstream support portion 60 is greater than a diameter d5 of the native valve (e.g., a diameter of the orifice of the native valve, e.g., an inner diameter of the annulus of the native valve). Further typically, diameter d4 of opening 61 is smaller than diameter d5. When prosthetic valve 150 is expanded within opening 61 of the upstream support portion, a diameter d6 of the prosthetic valve is typically restricted by the upstream support portion to the same diameter as diameter d4 of opening 61. For some applications, contact between prosthetic valve 150 and upstream support portion 60 (e.g., resulting from the radially-expansive force of the valve on the support) couples the prosthetic valve to the prosthetic valve support, and/or inhibits retrograde leakage of blood therebetween.
When implanted at the native valve (e.g., when in respective expanded configurations), a height d9 of prosthetic valve 150 is typically at least 1.5 times greater (e.g., at least 3 times greater, such as at least 5 times greater) than the total height of upstream support portion 60. Typically, height d9 is at least 1.5 times greater (e.g., at least 3 times greater, such as at least 5 times greater) than depth d10 of opening 61.
As described hereinabove, upstream support portion 60 is configured to be placed against an upstream side of the native valve. It should be noted, that radial expansion of prosthetic valve 150 against inner perimeter 68 of upstream support portion 60, thereby typically does not cause the prosthetic valve support to apply a radially-expansive force to the native valve annulus. For some applications of the invention, this expansion of prosthetic valve 150 does not cause the prosthetic valve support to apply the radially-expansive force to the native valve annulus because no part of the prosthetic valve support that circumscribes the prosthetic valve is sandwiched between the prosthetic valve and the native valve annulus.
For some applications, prosthetic valve 150 is couplable to upstream support portion 60 at a plurality of positions along the length of the prosthetic valve. That is, a physician can couple the prosthetic valve at a plurality of depths within the support. For some applications, the prosthetic valve is couplable to the upstream support portion at a continuum of positions along the length of the prosthetic valve. That is, a physician can couple the prosthetic valve to the support at a continuum of depths within the support. For example, in some applications in which the prosthetic valve is configured to be coupled to the upstream support portion solely by the radially-expansive force, the prosthetic valve may be coupled to the upstream support portion at a continuum of positions along the length of the prosthetic valve.
For some applications, sealing between implant 180 and native valve 120 is facilitated by native leaflets 128 being pushed closed against the outer surface of the frame of the valve during systole, in a manner similar to that in which native valve leaflets of a healthy native valve coapt during systole.
For applications in which diameters d4 and d6 are relatively large, the proportion (e.g., the surface area) of the native leaflets that is pushed against the outer surface of the valve during systole is relatively large, thereby enhancing the sealing of the native leaflets with respect to the frame of the prosthetic valve. However, for some applications, beyond a given size, as diameters d4 and d6 increase, the native valve leaflets are pushed apart at the commissures, thereby potentially increasing a likelihood of paravalvular retrograde leakage of blood at the commissures. Therefore, for some applications of the present invention, prosthetic valve support 22 (and, typically, prosthetic valve 150) are selected such that diameters d4 and d6 are less than 90% (e.g., 5 less than 80%, e.g., less than 60%, such as less than 50%) of diameter d5 of the native valve (e.g., of the orifice of the native valve). Thus prosthetic valve support 22 facilitates sealing of the prosthetic valve with respect to the native valve, by facilitating closing of the native valve leaflets around the outer surface of the prosthetic valve.
In experiments conducted by the inventors, a prosthetic valve support 22 was implanted in two pigs. Both animals remained alive and stable (e.g., were hemodynamically stable, and had stable breathing rate and oxygen saturation) for a duration of sufficient length to withdraw delivery apparatus 140, introduce a valve-delivery system, and deploy (e.g., implant) a prosthetic valve in opening 61 of the support. The period between implanting prosthetic valve support 22 and implanting the prosthetic valve was between 5 and 10 minutes. During this duration, the native valve of the animals functioned generally normally. For example, native leaflet movement and coaptation, and blood flow therebetween was generally normal during this duration.
It is thereby hypothesized that, following implantation of prosthetic valve support 22, the heart of the subject is able to continue pumping blood sufficiently to support the subject (e.g., to maintain hemodynamic stability) for longer than a minute, e.g., longer than 2 minutes, e.g., longer than 5 minutes, such as longer than an hour. It is thereby hypothesized that a period of generally normal physiological activity of the subject of up to a minute, e.g., up to 2 minutes, e.g., up to 5 minutes, such as up to an hour, between implantation of prosthetic valve support 22 and implantation of a prosthetic valve (e.g., prosthetic valve 150) is supported by prosthetic valve support 22. It is thereby hypothesized that, for some applications, the implantation of implant 180 may be performed without the use of cardiopulmonary bypass. It is thereby further hypothesized that replacement of a native valve with implant 180, may, for some applications, be performed in a human, “off-pump,” as was performed in the pig experiments.
Reference is again made to
As described hereinabove, coupling of prosthetic valve 150 to prosthetic valve support 22 is typically facilitated by radially-expansive force applied by the valve to the support. Typically, prosthetic valve 150 comprises an expandable lattice-structure frame 151 (e.g., comprising a plurality of struts). For applications of the invention in which upstream support portion 60 comprises inwardly-protruding barbs 67 (e.g., as shown in
Typically, at least portions of the inner surface of prosthetic valve 150 (e.g., of valve body 152) are covered with a covering 156, to facilitate channeling of blood through the valve body, as is known in the art. That is, at least portions of prosthetic valve 150 (e.g., of valve body 152) are lined with covering 156. Covering 156 may comprise the same material(s) as covering 64 described hereinabove, and/or may comprise other materials.
For some applications, an upstream portion of prosthetic valve 150 (e.g., of valve body 152) alternatively or additionally comprises a netting 158, which facilitates coupling of the prosthetic valve to prosthetic valve support 22. Netting 158 may be disposed on the inner surface and/or the outer surface of the upstream portion of the prosthetic valve (e.g., of valve body 152), and/or between the struts of frame 151. Typically, netting 158 is disposed upstream of a point at which leaflets 182 contact (e.g., seal around) valve body 152.
Typically, netting 158 facilitates coupling of prosthetic valve 150 to prosthetic valve support 22 by providing a higher-resolution lattice through which barbs 67 of the prosthetic valve support are configured to protrude. Netting 158 may additionally insulate respective metallic surfaces of the prosthetic valve and the prosthetic valve support (e.g., of frames 62 and 151) from each other. It is hypothesized that this insulation reduces fatigue, corrosion, chipping and/or wear of the metallic surfaces, and/or electrostatic discharge between the metallic surfaces.
For some applications, a material that inhibits (e.g., prevents) tissue growth (e.g., polytetrafluoroethylene (PTFE), and/or pericardium) may be disposed on a surface of prosthetic valve 150 and/or prosthetic valve support 22 (e.g., clips 30 thereof). Alternatively or additionally, a material that facilitates (e.g., enhances) tissue growth (such as polyethylene terephthalate; PET) may be disposed on a surface of the prosthetic valve and/or the prosthetic valve support (e.g., clips 30 thereof), in order to facilitate sealing and/or coupling to the native valve.
It is hypothesized that the use of prosthetic valve support 22 advantageously facilitates delivery of a prosthetic valve via a catheter narrower than 28 Fr (i.e., less than 9.3 mm), e.g., narrower than 24 Fr (i.e., less than 8 mm), such as by allowing the use of a “minimalistic” prosthetic valve, comprising a generally cylindrical valve body, and valve members (e.g., leaflets) disposed therein, and comprising few or no other components and/or appendages. Typically, prosthetic valve support 22 is also delivered via a similarly narrow catheter, e.g., via the same catheter. The use of such a narrow catheter advantageously facilitates transluminal (e.g., transfemoral) delivery and implantation of the prosthetic valve and prosthetic valve support.
It is to be noted that, although
Reference is made to
A portion (e.g., a middle portion) of each coupling lead 202 is disposed within (e.g., threaded and/or looped through) a respective portion of upstream support portion 60, thereby coupling the upstream support portion to holding members 134. Typically, this middle portion of each coupling lead is disposed through a peripheral region (e.g., close to an outer edge 69) of the prosthetic valve support.
For example, and as shown in
For some applications of the invention, system 200 is configured to facilitate transluminal retrieval of upstream support portion 60 following expansion of the upstream support portion at the native valve. Upstream support portion 60 is deployed at the native valve, e.g., as described with reference to
System 200 may alternatively or additionally be configured to facilitate controlled expansion of upstream support portion 60. During deployment of upstream support portion 60, coupling leads 202 are gradually released (e.g., fed distally). This technique may be understood by considering
It is to be noted that the techniques described with reference to
Reference is made to
For some applications of the invention, it may be desirable and/or necessary to hold clips 30 closer together than they would otherwise be disposed following complete release, and thereby expansion, of upstream support portion 60.
At a later time (e.g., closer to a time at which prosthetic valve 150 is to be implanted, such as at the time at which the prosthetic valve is implanted), coupling lead 210 is released, such that the upstream support portion (and the prosthetic valve support as a whole) moves toward the configuration shown in
For example, and as shown in
It is to be noted that the techniques described with reference to
Reference is made to
Subsequently (e.g., immediately subsequently, or after more than a minute, e.g., after more than 2 minutes, e.g., after more than 5 minutes, such as after more than an hour), a prosthetic valve is transluminally delivered, and implanted at the native valve by coupling the prosthetic valve to prosthetic valve support 522 (e.g., as described with reference to
For some applications of the invention, tissue-engaging elements 24 are coupled to each other by a locking element (e.g., a locking wire), and the locking element is unlocked (e.g., the locking wire is cut or otherwise decoupled), prior to implantation of the prosthetic valve support. For some applications of the invention, tissue-engaging elements 24 are coupled to each other by a coupling lead that which is held in place, and removed, decoupled, and/or loosened immediately prior to implantation of the prosthetic valve. For example, the coupling lead may extend through a holding member and be looped through and/or around the tissue-engaging elements. For some such applications, the holding member may comprise holding member 212, and the coupling lead may comprise coupling lead 210 (e.g., described with reference to
It is hypothesized that, following implantation of prosthetic valve support 522, the heart of the subject is able to continue pumping blood sufficiently to support the subject and/or to maintain hemodynamic stability for longer than a minute, e.g., longer than 2 minutes, e.g., longer than 5 minutes, such as longer than an hour. It is thereby hypothesized that a period of generally normal physiological activity of the subject of up to a minute (e.g., up to 2 minutes, e.g., up to 5 minutes, such as up to an hour) between implantation of prosthetic valve support 522 and implantation of a prosthetic valve, is supported by prosthetic valve support 522. It is thereby hypothesized that the implantation of an implant comprising prosthetic valve support 522 and a prosthetic valve, may be performed without the use of cardiopulmonary bypass. It is thereby hypothesized that replacement of a native valve with such an implant may be performed in a human, “off-pump.”
It is to be noted that the techniques described with reference to
Reference is made to
It is to be noted that the techniques described with reference to
Reference is made to
It is to be noted that the techniques described with reference to
Reference is made to
An engaging element 278 (e.g., a pawl, a ridge, or a tooth), typically within a ratchet housing 280, allows the length of holding wire 274 between the upstream support portion and the clip to be shortened, but not to be lengthened. Thereby, holding wire 274 (e.g., rack 276 thereof) and ratchet housing 280 (e.g., engaging element 278 thereof) act as a ratchet. For some applications, and as shown in
The length, elasticity and/or force constant of elastic elements 294 may be adapted to the native valve to which prosthetic valve support 290 is coupled, and/or to the individual subject (e.g., pre-selected according to the native valve and/or the individual subject). For example, elastic elements that have a relatively low force constant may allow leaflets of the native valve to move more freely, and elastic elements that have a relatively high force constant may couple the prosthetic valve support to the native valve more fixedly. Alternatively or additionally, connectors 260 may be configured to stretch and contract with movement (e.g., flapping) of the leaflets of the native valve, may thereby allow the leaflets to move more freely compared to some inelastic connectors, and may thereby facilitate the coupling of the prosthetic valve support to the native valve without eliminating check valve functionality of the native valve.
For some applications, restrictor 306 may be mechanically releasable (e.g., removable) by the user. For some applications, and as shown in
For some applications of the invention, prosthetic valve support 300 and connectors 302 are used in instances in which it is desirable to have a first period during which the connectors are longer (e.g., prior to implantation of a prosthetic valve), and a second period during which the connectors are shorter (e.g., subsequent to implantation of the prosthetic valve).
Reference is again made to
It is to be noted that the apparatus and techniques described with reference to
Reference is again made to
Reference is again made to
Reference is again made to
It is to be noted that, although some techniques described hereinabove are generally illustrated as being used at the mitral valve of the subject, the scope of the invention includes implanting a prosthetic valve support and prosthetic valve (e.g., those described hereinabove) at other native heart valves of the subject, such as at the tricuspid valve, the aortic valve, or the pulmonary valve of the subject, mutatis mutandis.
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
This application is a Continuation of U.S. Ser. No. 17/982,897 to Gross et al., filed Nov. 8, 2022, which published as US 2023/0058653, which is a Continuation of U.S. Ser. No. 16/888,210 to HaCohen, filed May 29, 2020, now U.S. Pat. No. 11,517,436, which is a Continuation of U.S. Ser. No. 16/284,331 to HaCohen, filed Feb. 25, 2019, now U.S. Pat. No. 10,702,385, which is a Continuation of U.S. Ser. No. 15/197,069 to Gross et al., filed Jun. 29, 2016, now U.S. Pat. No. 10,226,341, which is a Continuation of U.S. Ser. No. 14/237,258 to Gross et al., filed May 23, 2014, now U.S. Pat. No. 9,387,078, which is the US National Phase of PCT Patent Application IL2012/000293 to Gross et al., filed Aug. 5, 2012, which published as WO 2013/021375, and which: (1) claims priority from: U.S. 61/515,372 to Gross et al., filed Aug. 5, 2011;U.S. 61/525,281 to Gross et al., filed Aug. 19, 2011;U.S. 61/537,276 to Gross et al., filed Sep. 21, 2011;U.S. 61/555,160 to Gross et al., filed Nov. 3, 2011;U.S. 61/588,892 to Gross et al., filed Jan. 20, 2012; andU.S. Ser. No. 13/412,814 to Gross et al., filed Mar. 6, 2012, now U.S. Pat. No. 8,852,272, all of which are incorporated herein by reference; and(2) is a continuation-in-part of U.S. Ser. No. 13/412,814 to Gross et al., filed Mar. 6, 2012, now U.S. Pat. No. 8,852,272. This application is related to PCT application IL2012/000292 to Gross et al., entitled, “Techniques for percutaneous mitral valve replacement and sealing,” filed Aug. 5, 2012, which published as WO 2013/021374.
Number | Name | Date | Kind |
---|---|---|---|
3874388 | King et al. | Apr 1975 | A |
4222126 | Boretos et al. | Sep 1980 | A |
4261342 | Aranguren | Apr 1981 | A |
4340091 | Skelton et al. | Jul 1982 | A |
4423525 | Vallana et al. | Jan 1984 | A |
4853986 | Allen | Aug 1989 | A |
4892541 | Alonso | Jan 1990 | A |
4972494 | White et al. | Nov 1990 | A |
5108420 | Marks | Apr 1992 | A |
5314473 | Godin | May 1994 | A |
5405378 | Strecker | Apr 1995 | A |
5443500 | Sigwart | Aug 1995 | A |
5607444 | Lam | Mar 1997 | A |
5607470 | Milo | Mar 1997 | A |
5647857 | Anderson et al. | Jul 1997 | A |
5702397 | Goble et al. | Dec 1997 | A |
5713948 | Uflacker | Feb 1998 | A |
5716417 | Girard et al. | Feb 1998 | A |
5741297 | Simon | Apr 1998 | A |
5765682 | Bley et al. | Jun 1998 | A |
5776140 | Cottone | Jul 1998 | A |
5868777 | Lam | Feb 1999 | A |
5873906 | Lau et al. | Feb 1999 | A |
5954766 | Zadno-Azizi et al. | Sep 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5980565 | Jayaraman | Nov 1999 | A |
6010530 | Goicoechea | Jan 2000 | A |
6019787 | Richard et al. | Feb 2000 | A |
6042607 | Williamson, IV | Mar 2000 | A |
6074417 | Peredo | Jun 2000 | A |
6113612 | Swanson et al. | Sep 2000 | A |
6120534 | Ruiz | Sep 2000 | A |
6126686 | Badylak et al. | Oct 2000 | A |
6152937 | Peterson et al. | Nov 2000 | A |
6165183 | Kuehn et al. | Dec 2000 | A |
6165210 | Lau et al. | Dec 2000 | A |
6187020 | Zegdi et al. | Feb 2001 | B1 |
6193745 | Fogarty et al. | Feb 2001 | B1 |
6264700 | Kilcoyne et al. | Jul 2001 | B1 |
6287339 | Vasquez et al. | Sep 2001 | B1 |
6312465 | Griffin et al. | Nov 2001 | B1 |
6332893 | Mortier et al. | Dec 2001 | B1 |
6334873 | Lane et al. | Jan 2002 | B1 |
6346074 | Roth | Feb 2002 | B1 |
6350278 | Lenker et al. | Feb 2002 | B1 |
6352561 | Leopold et al. | Mar 2002 | B1 |
6391036 | Berg et al. | May 2002 | B1 |
6402780 | Williamson, IV | Jun 2002 | B2 |
6409755 | Vrba | Jun 2002 | B1 |
6419696 | Ortiz et al. | Jul 2002 | B1 |
6428550 | Vargas et al. | Aug 2002 | B1 |
6440164 | Dimatteo et al. | Aug 2002 | B1 |
6454799 | Schreck | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6511491 | Grudem et al. | Jan 2003 | B2 |
6530952 | Vesely | Mar 2003 | B2 |
6540782 | Snyders | Apr 2003 | B1 |
6551350 | Thornton et al. | Apr 2003 | B1 |
6558396 | Inoue | May 2003 | B1 |
6558418 | Carpentier et al. | May 2003 | B2 |
6569196 | Vesely | May 2003 | B1 |
6582464 | Gabbay | Jun 2003 | B2 |
6602263 | Swanson et al. | Aug 2003 | B1 |
6616675 | Evard et al. | Sep 2003 | B1 |
6629534 | St. Goar et al. | Oct 2003 | B1 |
6652556 | VanTessel et al. | Nov 2003 | B1 |
6669724 | Park et al. | Dec 2003 | B2 |
6682558 | Tu et al. | Jan 2004 | B2 |
6699256 | Logan et al. | Mar 2004 | B1 |
6716244 | Klaco | Apr 2004 | B2 |
6719781 | Kim | Apr 2004 | B1 |
6730118 | Spenser et al. | May 2004 | B2 |
6730121 | Ortiz et al. | May 2004 | B2 |
6733525 | Yang et al. | May 2004 | B2 |
6752813 | Goldfarb et al. | Jun 2004 | B2 |
6764514 | Li et al. | Jul 2004 | B1 |
6764518 | Godin | Jul 2004 | B2 |
6767362 | Schreck | Jul 2004 | B2 |
6797002 | Spence et al. | Sep 2004 | B2 |
6821297 | Snyders | Nov 2004 | B2 |
6830585 | Artof et al. | Dec 2004 | B1 |
6830638 | Boylan et al. | Dec 2004 | B2 |
6893460 | Spenser et al. | May 2005 | B2 |
6926715 | Hauck et al. | Aug 2005 | B1 |
6951571 | Srivastava | Oct 2005 | B1 |
6960217 | Bolduc | Nov 2005 | B2 |
6964684 | Ortiz et al. | Nov 2005 | B2 |
6974476 | McGuckin et al. | Dec 2005 | B2 |
7011681 | Vesely | Mar 2006 | B2 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7041132 | Quijano et al. | May 2006 | B2 |
7077861 | Spence | Jul 2006 | B2 |
7101336 | Miller | Sep 2006 | B2 |
7101395 | Tremulis et al. | Sep 2006 | B2 |
7101396 | Artof et al. | Sep 2006 | B2 |
7112207 | Allen et al. | Sep 2006 | B2 |
7137184 | Schreck | Nov 2006 | B2 |
7172625 | Shu et al. | Feb 2007 | B2 |
7198646 | Figulla et al. | Apr 2007 | B2 |
7201772 | Schwammenthal | Apr 2007 | B2 |
7226467 | Lucatero et al. | Jun 2007 | B2 |
7226477 | Cox | Jun 2007 | B2 |
7261686 | Couvillon, Jr. | Aug 2007 | B2 |
7288097 | Séguin | Oct 2007 | B2 |
7288111 | Holloway et al. | Oct 2007 | B1 |
7316716 | Egan | Jan 2008 | B2 |
7329279 | Haug et al. | Feb 2008 | B2 |
7335213 | Hyde et al. | Feb 2008 | B1 |
7351256 | Hojeibane et al. | Apr 2008 | B2 |
7374571 | Pease et al. | May 2008 | B2 |
7374573 | Gabbay | May 2008 | B2 |
7377938 | Sarac et al. | May 2008 | B2 |
7381218 | Schreck | Jun 2008 | B2 |
7381219 | Salahieh et al. | Jun 2008 | B2 |
7404824 | Webler et al. | Jul 2008 | B1 |
7422306 | Lane | Sep 2008 | B2 |
7429269 | Schwammenthal | Sep 2008 | B2 |
7442204 | Schwammenthal | Oct 2008 | B2 |
7445630 | Lashinski et al. | Nov 2008 | B2 |
7455677 | Vargas et al. | Nov 2008 | B2 |
7455688 | Furst et al. | Nov 2008 | B2 |
7462162 | Phan et al. | Dec 2008 | B2 |
7481838 | Carpentier et al. | Jan 2009 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7513909 | Lane et al. | Apr 2009 | B2 |
7524331 | Birdsall | Apr 2009 | B2 |
7527646 | Rahdert et al. | May 2009 | B2 |
7556632 | Zadno | Jul 2009 | B2 |
7556646 | Yang et al. | Jul 2009 | B2 |
7563267 | Goldfarb et al. | Jul 2009 | B2 |
7563273 | Goldfarb et al. | Jul 2009 | B2 |
7582111 | Krolik et al. | Sep 2009 | B2 |
7585321 | Cribier | Sep 2009 | B2 |
7597711 | Drews et al. | Oct 2009 | B2 |
7608091 | Goldfarb et al. | Oct 2009 | B2 |
7611534 | Kapadia et al. | Nov 2009 | B2 |
7621948 | Hermann et al. | Nov 2009 | B2 |
7625403 | Krivoruchko | Dec 2009 | B2 |
7632302 | Vreeman et al. | Dec 2009 | B2 |
7635329 | Goldfarb et al. | Dec 2009 | B2 |
7648528 | Styrc | Jan 2010 | B2 |
7655015 | Goldfarb et al. | Feb 2010 | B2 |
7666204 | Thornton et al. | Feb 2010 | B2 |
7682380 | Thornton et al. | Mar 2010 | B2 |
7708775 | Rowe et al. | May 2010 | B2 |
7717952 | Case et al. | May 2010 | B2 |
7717955 | Lane et al. | May 2010 | B2 |
7731741 | Eidenschink | Jun 2010 | B2 |
7736388 | Goldfarb et al. | Jun 2010 | B2 |
7748389 | Salahieh et al. | Jul 2010 | B2 |
7753922 | Starksen | Jul 2010 | B2 |
7753949 | Lamphere et al. | Jul 2010 | B2 |
7758595 | Allen et al. | Jul 2010 | B2 |
7758632 | Hojeibane et al. | Jul 2010 | B2 |
7758640 | Vesely | Jul 2010 | B2 |
7771467 | Svensson | Aug 2010 | B2 |
7771469 | Liddicoat | Aug 2010 | B2 |
7776083 | Vesely | Aug 2010 | B2 |
7780726 | Seguin | Aug 2010 | B2 |
7799069 | Bailey et al. | Sep 2010 | B2 |
7803181 | Furst et al. | Sep 2010 | B2 |
7811296 | Goldfarb et al. | Oct 2010 | B2 |
7811316 | Kalmann et al. | Oct 2010 | B2 |
7824442 | Salahieh et al. | Nov 2010 | B2 |
7837645 | Bessler et al. | Nov 2010 | B2 |
7837727 | Goetz et al. | Nov 2010 | B2 |
7842081 | Yadin | Nov 2010 | B2 |
7850725 | Vardi et al. | Dec 2010 | B2 |
7871432 | Bergin | Jan 2011 | B2 |
7871436 | Ryan et al. | Jan 2011 | B2 |
7887583 | Macoviak | Feb 2011 | B2 |
7892281 | Seguin et al. | Feb 2011 | B2 |
7896915 | Guyenot et al. | Mar 2011 | B2 |
7914544 | Nguyen et al. | Mar 2011 | B2 |
7914569 | Nguyen et al. | Mar 2011 | B2 |
7927370 | Webler et al. | Apr 2011 | B2 |
7942927 | Kaye et al. | May 2011 | B2 |
7947072 | Yang et al. | May 2011 | B2 |
7947075 | Goetz et al. | May 2011 | B2 |
7951195 | Antonsson et al. | May 2011 | B2 |
7955375 | Agnew | Jun 2011 | B2 |
7955377 | Melsheimer | Jun 2011 | B2 |
7955384 | Rafiee et al. | Jun 2011 | B2 |
7959666 | Salahieh et al. | Jun 2011 | B2 |
7959672 | Salahieh et al. | Jun 2011 | B2 |
7967833 | Sterman et al. | Jun 2011 | B2 |
7967857 | Lane | Jun 2011 | B2 |
7981151 | Rowe | Jul 2011 | B2 |
7981153 | Fogarty et al. | Jul 2011 | B2 |
7992567 | Hirotsuka et al. | Aug 2011 | B2 |
7993393 | Carpentier et al. | Aug 2011 | B2 |
8002825 | Letac et al. | Aug 2011 | B2 |
8002826 | Seguin | Aug 2011 | B2 |
8016877 | Seguin et al. | Sep 2011 | B2 |
8016882 | Macoviak | Sep 2011 | B2 |
8021420 | Dolan | Sep 2011 | B2 |
8021421 | Fogarty et al. | Sep 2011 | B2 |
8025695 | Fogarty et al. | Sep 2011 | B2 |
8029518 | Goldfarb et al. | Oct 2011 | B2 |
8029557 | Sobrino-Serrano et al. | Oct 2011 | B2 |
8029564 | Johnson et al. | Oct 2011 | B2 |
8034104 | Carpentier et al. | Oct 2011 | B2 |
8038720 | Wallace et al. | Oct 2011 | B2 |
8043360 | McNamara et al. | Oct 2011 | B2 |
8048138 | Sulivan et al. | Nov 2011 | B2 |
8048140 | Purdy | Nov 2011 | B2 |
8048153 | Salahieh et al. | Nov 2011 | B2 |
8052592 | Goldfarb et al. | Nov 2011 | B2 |
8052741 | Bruszewski et al. | Nov 2011 | B2 |
8052749 | Salahieh et al. | Nov 2011 | B2 |
8057493 | Goldfarb et al. | Nov 2011 | B2 |
8057532 | Hoffman | Nov 2011 | B2 |
8057540 | Letac et al. | Nov 2011 | B2 |
8062355 | Figulla et al. | Nov 2011 | B2 |
8062359 | Marquez et al. | Nov 2011 | B2 |
8070708 | Rottenberg et al. | Dec 2011 | B2 |
8070800 | Lock et al. | Dec 2011 | B2 |
8070802 | Lamphere et al. | Dec 2011 | B2 |
8070804 | Hyde | Dec 2011 | B2 |
8075611 | Milwee et al. | Dec 2011 | B2 |
8080054 | Rowe | Dec 2011 | B2 |
8083793 | Lane et al. | Dec 2011 | B2 |
D652927 | Braido et al. | Jan 2012 | S |
D653341 | Braido et al. | Jan 2012 | S |
8092518 | Schreck | Jan 2012 | B2 |
8092520 | Quadri | Jan 2012 | B2 |
8092521 | Figulla et al. | Jan 2012 | B2 |
8105377 | Liddicoat | Jan 2012 | B2 |
8109996 | Stacchino et al. | Feb 2012 | B2 |
8118866 | Herrmann et al. | Feb 2012 | B2 |
8133270 | Kheradvar et al. | Mar 2012 | B2 |
8136218 | Millwee et al. | Mar 2012 | B2 |
8137398 | Tuval et al. | Mar 2012 | B2 |
8142492 | Forster et al. | Mar 2012 | B2 |
8142494 | Rahdert et al. | Mar 2012 | B2 |
8142496 | Berreklouw | Mar 2012 | B2 |
8142497 | Friedman | Mar 2012 | B2 |
8147504 | Ino et al. | Apr 2012 | B2 |
8157852 | Bloom et al. | Apr 2012 | B2 |
8157853 | Laske et al. | Apr 2012 | B2 |
8157860 | McNamara et al. | Apr 2012 | B2 |
8163008 | Wilson et al. | Apr 2012 | B2 |
8163014 | Lane et al. | Apr 2012 | B2 |
D660433 | Braido et al. | May 2012 | S |
D660967 | Braido et al. | May 2012 | S |
8167894 | Miles et al. | May 2012 | B2 |
8167932 | Bourang et al. | May 2012 | B2 |
8167935 | McGuckin, Jr. et al. | May 2012 | B2 |
8172896 | McNamara et al. | May 2012 | B2 |
8172898 | Alferness et al. | May 2012 | B2 |
8177836 | Lee et al. | May 2012 | B2 |
8182528 | Salahieh et al. | May 2012 | B2 |
8211169 | Lane et al. | Jul 2012 | B2 |
8216256 | Raschdorf, Jr. et al. | Jul 2012 | B2 |
8216301 | Bonhoeffer et al. | Jul 2012 | B2 |
8221492 | Case et al. | Jul 2012 | B2 |
8221493 | Boyle et al. | Jul 2012 | B2 |
8226710 | Nguyen et al. | Jul 2012 | B2 |
8231670 | Salahieh et al. | Jul 2012 | B2 |
8236045 | Benichou et al. | Aug 2012 | B2 |
8236049 | Rowe et al. | Aug 2012 | B2 |
8252042 | McNamara et al. | Aug 2012 | B2 |
8252051 | Chau et al. | Aug 2012 | B2 |
8252052 | Salahieh et al. | Aug 2012 | B2 |
8257390 | Carley et al. | Sep 2012 | B2 |
8267988 | Hamer et al. | Sep 2012 | B2 |
8277501 | Chalekian et al. | Oct 2012 | B2 |
8287591 | Keidar et al. | Oct 2012 | B2 |
8298280 | Yadin et al. | Oct 2012 | B2 |
8303653 | Bonhoeffer et al. | Nov 2012 | B2 |
8308798 | Pintor et al. | Nov 2012 | B2 |
8317853 | Agnew | Nov 2012 | B2 |
8317855 | Gregorich et al. | Nov 2012 | B2 |
8323335 | Rowe et al. | Dec 2012 | B2 |
8328868 | Paul et al. | Dec 2012 | B2 |
8337541 | Quadri et al. | Dec 2012 | B2 |
8343174 | Goldfard et al. | Jan 2013 | B2 |
8343213 | Salahieh et al. | Jan 2013 | B2 |
8348999 | Kheradvar et al. | Jan 2013 | B2 |
8366767 | Zhang | Feb 2013 | B2 |
8372140 | Hoffman et al. | Feb 2013 | B2 |
8377119 | Drews et al. | Feb 2013 | B2 |
8398708 | Meiri et al. | Mar 2013 | B2 |
8403981 | Forster et al. | Mar 2013 | B2 |
8403983 | Quadri et al. | Mar 2013 | B2 |
8408214 | Spenser | Apr 2013 | B2 |
8414644 | Quadri et al. | Apr 2013 | B2 |
8425593 | Braido | Apr 2013 | B2 |
8430934 | Das | Apr 2013 | B2 |
8444689 | Zhang | May 2013 | B2 |
8449599 | Chau et al. | May 2013 | B2 |
8449625 | Campbell et al. | May 2013 | B2 |
8454686 | Alkhatib | Jun 2013 | B2 |
8460365 | Haverkost et al. | Jun 2013 | B2 |
8474460 | Barrett et al. | Jul 2013 | B2 |
8500821 | Sobrino-Serrano et al. | Aug 2013 | B2 |
8512400 | Tran et al. | Aug 2013 | B2 |
8529431 | Baker et al. | Sep 2013 | B2 |
8539662 | Stacchino et al. | Sep 2013 | B2 |
8545544 | Spenser et al. | Oct 2013 | B2 |
8551160 | Figulla et al. | Oct 2013 | B2 |
8551161 | Dolan | Oct 2013 | B2 |
8562672 | Bonhoeffer et al. | Oct 2013 | B2 |
8568475 | Nguyen et al. | Oct 2013 | B2 |
8579964 | Lane et al. | Nov 2013 | B2 |
8579965 | Bonhoeffer et al. | Nov 2013 | B2 |
8585755 | Chau et al. | Nov 2013 | B2 |
8585756 | Bonhoeffer et al. | Nov 2013 | B2 |
8591460 | Wilson et al. | Nov 2013 | B2 |
8591570 | Revuelta et al. | Nov 2013 | B2 |
8623075 | Murray et al. | Jan 2014 | B2 |
8623080 | Fogarty et al. | Jan 2014 | B2 |
8628569 | Benichou et al. | Jan 2014 | B2 |
8628570 | Seguin | Jan 2014 | B2 |
8628571 | Hacohen et al. | Jan 2014 | B1 |
8652203 | Quadri et al. | Feb 2014 | B2 |
8652204 | Quill et al. | Feb 2014 | B2 |
8657872 | Seguin | Feb 2014 | B2 |
8663322 | Keranen | Mar 2014 | B2 |
8673020 | Sobrino-Serrano et al. | Mar 2014 | B2 |
8679174 | Ottma et al. | Mar 2014 | B2 |
8685086 | Navia et al. | Apr 2014 | B2 |
8696742 | Pintor et al. | Apr 2014 | B2 |
8728155 | Montorfano et al. | May 2014 | B2 |
8734507 | Keranen | May 2014 | B2 |
8747460 | Tuval et al. | Jun 2014 | B2 |
8771345 | Tuval et al. | Jul 2014 | B2 |
8784472 | Eidenschink | Jul 2014 | B2 |
8784479 | Antonsson et al. | Jul 2014 | B2 |
8784481 | Alkhatib et al. | Jul 2014 | B2 |
8795355 | Alkhatib | Aug 2014 | B2 |
8795356 | Quadri et al. | Aug 2014 | B2 |
8795357 | Yohanan et al. | Aug 2014 | B2 |
8801776 | House et al. | Aug 2014 | B2 |
8808366 | Braido et al. | Aug 2014 | B2 |
8840663 | Salahieh et al. | Sep 2014 | B2 |
8840664 | Karapetian et al. | Sep 2014 | B2 |
8845722 | Gabbay | Sep 2014 | B2 |
8852261 | White | Oct 2014 | B2 |
8852272 | Gross | Oct 2014 | B2 |
8870948 | Erzberger et al. | Oct 2014 | B1 |
8870949 | Rowe | Oct 2014 | B2 |
8870950 | Hacohen | Oct 2014 | B2 |
8876800 | Behan | Nov 2014 | B2 |
8888843 | Khairkhahan et al. | Nov 2014 | B2 |
8894702 | Quadri et al. | Nov 2014 | B2 |
8900294 | Paniagua et al. | Dec 2014 | B2 |
8900295 | Migliazza et al. | Dec 2014 | B2 |
8906083 | Obermiller et al. | Dec 2014 | B2 |
8911455 | Quadri et al. | Dec 2014 | B2 |
8911489 | Ben-Muvhar | Dec 2014 | B2 |
8911493 | Rowe et al. | Dec 2014 | B2 |
8932343 | Alkhatib et al. | Jan 2015 | B2 |
8945177 | Dell et al. | Feb 2015 | B2 |
8961595 | Alkhatib | Feb 2015 | B2 |
8979922 | Jayasinghe et al. | Mar 2015 | B2 |
8986370 | Annest | Mar 2015 | B2 |
8986373 | Chau et al. | Mar 2015 | B2 |
8986375 | Garde et al. | Mar 2015 | B2 |
8992599 | Thubrikar et al. | Mar 2015 | B2 |
8992604 | Gross | Mar 2015 | B2 |
8992608 | Haug et al. | Mar 2015 | B2 |
8998982 | Richter | Apr 2015 | B2 |
9005273 | Salahieh et al. | Apr 2015 | B2 |
9011468 | Ketai et al. | Apr 2015 | B2 |
9011527 | Li et al. | Apr 2015 | B2 |
9017399 | Gross | Apr 2015 | B2 |
D730520 | Braido et al. | May 2015 | S |
D730521 | Braido et al. | May 2015 | S |
9023100 | Quadri | May 2015 | B2 |
9034032 | McLean et al. | May 2015 | B2 |
9034033 | McLean et al. | May 2015 | B2 |
9039757 | McLean et al. | May 2015 | B2 |
D732666 | Nguyen et al. | Jun 2015 | S |
9050188 | Schweich et al. | Jun 2015 | B2 |
9060858 | Thornton et al. | Jun 2015 | B2 |
9072603 | Tuval et al. | Jul 2015 | B2 |
9084676 | Chau et al. | Jul 2015 | B2 |
9095434 | Rowe | Aug 2015 | B2 |
9119719 | Zipory | Sep 2015 | B2 |
9125738 | Figulla et al. | Sep 2015 | B2 |
9125740 | Morriss et al. | Sep 2015 | B2 |
9132006 | Spenser et al. | Sep 2015 | B2 |
9132009 | Hacohen | Sep 2015 | B2 |
9138312 | Tuval et al. | Sep 2015 | B2 |
9155619 | Liu et al. | Oct 2015 | B2 |
9173659 | Bodewadt et al. | Nov 2015 | B2 |
9173738 | Murray et al. | Nov 2015 | B2 |
9220594 | Braido et al. | Dec 2015 | B2 |
9226820 | Braido et al. | Jan 2016 | B2 |
9226839 | Kariniemi et al. | Jan 2016 | B1 |
9232995 | Kovalsky et al. | Jan 2016 | B2 |
9241790 | Lane et al. | Jan 2016 | B2 |
9241791 | Braido et al. | Jan 2016 | B2 |
9241792 | Benichou et al. | Jan 2016 | B2 |
9241794 | Braido et al. | Jan 2016 | B2 |
9248014 | Lane et al. | Feb 2016 | B2 |
9277994 | Miller | Mar 2016 | B2 |
9289290 | Alkhatib et al. | Mar 2016 | B2 |
9289291 | Gorman et al. | Mar 2016 | B2 |
9295550 | Nguyen et al. | Mar 2016 | B2 |
9295551 | Straubinger et al. | Mar 2016 | B2 |
9295552 | McLean et al. | Mar 2016 | B2 |
9301836 | Buchbinder et al. | Apr 2016 | B2 |
D755384 | Pesce et al. | May 2016 | S |
9326852 | Spenser | May 2016 | B2 |
9326876 | Acosta et al. | May 2016 | B2 |
9345573 | Nyuli et al. | May 2016 | B2 |
9387078 | Gross | Jul 2016 | B2 |
9421098 | Gifford et al. | Aug 2016 | B2 |
9427303 | Liddy et al. | Aug 2016 | B2 |
9427316 | Schweich, Jr. et al. | Aug 2016 | B2 |
9439757 | Wallace et al. | Sep 2016 | B2 |
9463102 | Kelly | Oct 2016 | B2 |
9474599 | Keranen | Oct 2016 | B2 |
9474638 | Robinson et al. | Oct 2016 | B2 |
9480559 | Vidlund et al. | Nov 2016 | B2 |
9492273 | Wallace et al. | Nov 2016 | B2 |
9498314 | Behan | Nov 2016 | B2 |
9532870 | Cooper et al. | Jan 2017 | B2 |
9554897 | Lane et al. | Jan 2017 | B2 |
9554899 | Granada et al. | Jan 2017 | B2 |
9561103 | Granada et al. | Feb 2017 | B2 |
9566152 | Schweich et al. | Feb 2017 | B2 |
9629716 | Seguin | Apr 2017 | B2 |
9662203 | Sheahan et al. | May 2017 | B2 |
9681952 | Hacohen et al. | Jun 2017 | B2 |
9717591 | Chau et al. | Aug 2017 | B2 |
9743932 | Amplatz et al. | Aug 2017 | B2 |
9763657 | Hacohen | Sep 2017 | B2 |
9763817 | Roeder | Sep 2017 | B2 |
9770256 | Cohen et al. | Sep 2017 | B2 |
D800908 | Hariton et al. | Oct 2017 | S |
9788941 | Hacohen | Oct 2017 | B2 |
9895226 | Harari et al. | Feb 2018 | B1 |
9987132 | Hariton et al. | Jun 2018 | B1 |
10010414 | Cooper et al. | Jul 2018 | B2 |
10105222 | Metchik et al. | Oct 2018 | B1 |
10123873 | Metchik et al. | Nov 2018 | B1 |
10143552 | Wallace et al. | Dec 2018 | B2 |
10149761 | Granada et al. | Dec 2018 | B2 |
10154906 | Granada et al. | Dec 2018 | B2 |
10182908 | Tubishevitz et al. | Jan 2019 | B2 |
10206668 | Mcgoldrick et al. | Feb 2019 | B2 |
10226341 | Gross | Mar 2019 | B2 |
10245143 | Gross et al. | Apr 2019 | B2 |
10258471 | Lutter et al. | Apr 2019 | B2 |
10292816 | Raanani et al. | May 2019 | B2 |
10321995 | Christianson et al. | Jun 2019 | B1 |
10322020 | Lam et al. | Jun 2019 | B2 |
10327895 | Lozonschi et al. | Jun 2019 | B2 |
10376361 | Gross | Aug 2019 | B2 |
10390952 | Hariton et al. | Aug 2019 | B2 |
10456256 | Braido et al. | Oct 2019 | B2 |
10507108 | Delgado et al. | Dec 2019 | B2 |
10512456 | Hacohen | Dec 2019 | B2 |
10517719 | Miller | Dec 2019 | B2 |
10531866 | Hariton et al. | Jan 2020 | B2 |
10531872 | Hacohen et al. | Jan 2020 | B2 |
10548731 | Lashinski et al. | Feb 2020 | B2 |
10575948 | Iamberger et al. | Mar 2020 | B2 |
10595992 | Chambers | Mar 2020 | B2 |
10610358 | Vidlund et al. | Apr 2020 | B2 |
10631871 | Goldfarb et al. | Apr 2020 | B2 |
10667912 | Dixon et al. | Jun 2020 | B2 |
10695173 | Gross et al. | Jun 2020 | B2 |
10702385 | Hacohen | Jul 2020 | B2 |
10835377 | Hacohen et al. | Nov 2020 | B2 |
10842627 | Delgado et al. | Nov 2020 | B2 |
10856972 | Hariton et al. | Dec 2020 | B2 |
10874514 | Dixon et al. | Dec 2020 | B2 |
10888422 | Hariton et al. | Jan 2021 | B2 |
10888425 | Delgado et al. | Jan 2021 | B2 |
10888644 | Ratz et al. | Jan 2021 | B2 |
10905552 | Dixon et al. | Feb 2021 | B2 |
10905554 | Cao | Feb 2021 | B2 |
10918483 | Metchik et al. | Feb 2021 | B2 |
10925732 | Delgado et al. | Feb 2021 | B2 |
10945843 | Delgado et al. | Mar 2021 | B2 |
10945844 | McCann et al. | Mar 2021 | B2 |
10959846 | Marr et al. | Mar 2021 | B2 |
10993809 | McCann et al. | May 2021 | B2 |
11065114 | Raanani et al. | Jul 2021 | B2 |
11083582 | McCann et al. | Aug 2021 | B2 |
11147672 | McCann et al. | Oct 2021 | B2 |
11179240 | Delgado et al. | Nov 2021 | B2 |
11291545 | Hacohen | Apr 2022 | B2 |
11291546 | Gross | Apr 2022 | B2 |
11291547 | Gross | Apr 2022 | B2 |
11291844 | Gross | Apr 2022 | B2 |
11304806 | Hariton et al. | Apr 2022 | B2 |
11389297 | Franklin et al. | Jul 2022 | B2 |
11426155 | Hacohen | Aug 2022 | B2 |
11517429 | Gross | Dec 2022 | B2 |
11517436 | Hacohen | Dec 2022 | B2 |
20010002445 | Vesely | May 2001 | A1 |
20010005787 | Oz | Jun 2001 | A1 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20010056295 | Solem | Dec 2001 | A1 |
20020013571 | Goldfarb et al. | Jan 2002 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020099436 | Thornton et al. | Jul 2002 | A1 |
20020151970 | Garrison et al. | Oct 2002 | A1 |
20020177894 | Acosta et al. | Nov 2002 | A1 |
20030009236 | Godin | Jan 2003 | A1 |
20030036791 | Bonhoefter et al. | Feb 2003 | A1 |
20030060846 | Egnelov et al. | Mar 2003 | A1 |
20030060875 | Wittens | Mar 2003 | A1 |
20030069635 | Cartledge | Apr 2003 | A1 |
20030074052 | Besselink | Apr 2003 | A1 |
20030083742 | Spence et al. | May 2003 | A1 |
20030105519 | Fasol et al. | Jun 2003 | A1 |
20030120340 | Liska et al. | Jun 2003 | A1 |
20030158578 | Pantages et al. | Aug 2003 | A1 |
20040010272 | Manetakis et al. | Jan 2004 | A1 |
20040030382 | St. Goar et al. | Feb 2004 | A1 |
20040039414 | Carley et al. | Feb 2004 | A1 |
20040039442 | St. Goar et al. | Feb 2004 | A1 |
20040093060 | Seguin et al. | May 2004 | A1 |
20040122503 | Campbell et al. | Jun 2004 | A1 |
20040122514 | Fogarty et al. | Jun 2004 | A1 |
20040133267 | Lane | Jul 2004 | A1 |
20040143315 | Bruun et al. | Jul 2004 | A1 |
20040176839 | Huynh et al. | Sep 2004 | A1 |
20040186558 | Pavcnik et al. | Sep 2004 | A1 |
20040186565 | Schreck | Sep 2004 | A1 |
20040186566 | Hindrichs et al. | Sep 2004 | A1 |
20040210244 | Vargas et al. | Oct 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040220593 | Greenhalgh | Nov 2004 | A1 |
20040225354 | Allen et al. | Nov 2004 | A1 |
20040236354 | Seguin | Nov 2004 | A1 |
20040249433 | Freitag | Dec 2004 | A1 |
20040260389 | Case et al. | Dec 2004 | A1 |
20040260394 | Douk et al. | Dec 2004 | A1 |
20050004668 | Aklog et al. | Jan 2005 | A1 |
20050021056 | St. Goar et al. | Jan 2005 | A1 |
20050027305 | Shiu et al. | Feb 2005 | A1 |
20050027348 | Case et al. | Feb 2005 | A1 |
20050038494 | Eidenschink | Feb 2005 | A1 |
20050055086 | Stobie | Mar 2005 | A1 |
20050075731 | Artof et al. | Apr 2005 | A1 |
20050080430 | Wright et al. | Apr 2005 | A1 |
20050085900 | Case et al. | Apr 2005 | A1 |
20050137686 | Salahieh et al. | Jun 2005 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20050137689 | Salahieh et al. | Jun 2005 | A1 |
20050137690 | Salahieh et al. | Jun 2005 | A1 |
20050137691 | Salahieh et al. | Jun 2005 | A1 |
20050137692 | Haug et al. | Jun 2005 | A1 |
20050137693 | Haug et al. | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050137697 | Salahieh et al. | Jun 2005 | A1 |
20050137699 | Salahieh et al. | Jun 2005 | A1 |
20050143809 | Salahieh et al. | Jun 2005 | A1 |
20050149160 | McFerran | Jul 2005 | A1 |
20050154443 | Linder et al. | Jul 2005 | A1 |
20050182486 | Gabbay | Aug 2005 | A1 |
20050197695 | Stacchino et al. | Sep 2005 | A1 |
20050203549 | Realyvasquez | Sep 2005 | A1 |
20050203618 | Sharkawy et al. | Sep 2005 | A1 |
20050216079 | MaCoviak | Sep 2005 | A1 |
20050234508 | Cummins et al. | Oct 2005 | A1 |
20050240200 | Bergheim | Oct 2005 | A1 |
20050251251 | Cribier | Nov 2005 | A1 |
20050256566 | Gabbay | Nov 2005 | A1 |
20050267573 | Macoviak et al. | Dec 2005 | A9 |
20060004439 | Spenser et al. | Jan 2006 | A1 |
20060004469 | Sokel | Jan 2006 | A1 |
20060015171 | Armstrong | Jan 2006 | A1 |
20060020275 | Goldfarb et al. | Jan 2006 | A1 |
20060020327 | Lashinski et al. | Jan 2006 | A1 |
20060020333 | Lashinski et al. | Jan 2006 | A1 |
20060041189 | Vancaillie | Feb 2006 | A1 |
20060052867 | Revuelta et al. | Mar 2006 | A1 |
20060089627 | Burnett et al. | Apr 2006 | A1 |
20060111773 | Rittgers et al. | May 2006 | A1 |
20060116750 | Herbert et al. | Jun 2006 | A1 |
20060122692 | Gilad et al. | Jun 2006 | A1 |
20060135964 | Vesley | Jun 2006 | A1 |
20060155357 | Melsheimer | Jul 2006 | A1 |
20060047297 | Case | Aug 2006 | A1 |
20060178700 | Quinn | Aug 2006 | A1 |
20060178740 | Stacchino et al. | Aug 2006 | A1 |
20060184203 | Martin et al. | Aug 2006 | A1 |
20060190036 | Wendel et al. | Aug 2006 | A1 |
20060190038 | Carley et al. | Aug 2006 | A1 |
20060195183 | Navia et al. | Aug 2006 | A1 |
20060195184 | Lane et al. | Aug 2006 | A1 |
20060201519 | Frazier et al. | Sep 2006 | A1 |
20060212111 | Case et al. | Sep 2006 | A1 |
20060229708 | Powell et al. | Oct 2006 | A1 |
20060241656 | Starksen et al. | Oct 2006 | A1 |
20060241745 | Solem | Oct 2006 | A1 |
20060241748 | Lee et al. | Oct 2006 | A1 |
20060247680 | Amplatz et al. | Nov 2006 | A1 |
20060253191 | Salahieh et al. | Nov 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20060259137 | Artof | Nov 2006 | A1 |
20060271166 | Thill et al. | Nov 2006 | A1 |
20060271171 | McQuinn et al. | Nov 2006 | A1 |
20060282150 | Olson et al. | Dec 2006 | A1 |
20060287719 | Rowe et al. | Dec 2006 | A1 |
20070016286 | Herrmann et al. | Jan 2007 | A1 |
20070016288 | Gurskis et al. | Jan 2007 | A1 |
20070027528 | Agnew | Feb 2007 | A1 |
20070027549 | Godin | Feb 2007 | A1 |
20070038293 | St. Goar et al. | Feb 2007 | A1 |
20070038295 | Case et al. | Feb 2007 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070055340 | Pryor | Mar 2007 | A1 |
20070056346 | Spenser et al. | Mar 2007 | A1 |
20070078510 | Ryan | Apr 2007 | A1 |
20070112422 | Dehdashtian | May 2007 | A1 |
20070118151 | Davidson | May 2007 | A1 |
20070162103 | Case et al. | Jul 2007 | A1 |
20070162107 | Haug et al. | Jul 2007 | A1 |
20070162111 | Fukamachi et al. | Jul 2007 | A1 |
20070173932 | Cali et al. | Jul 2007 | A1 |
20070197858 | Goldfarb et al. | Aug 2007 | A1 |
20070198077 | Cully et al. | Aug 2007 | A1 |
20070198097 | Zegdi | Aug 2007 | A1 |
20070213810 | Newhauser et al. | Sep 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070219630 | Chu | Sep 2007 | A1 |
20070225759 | Thommen et al. | Sep 2007 | A1 |
20070225760 | Moszner et al. | Sep 2007 | A1 |
20070233186 | Meng | Oct 2007 | A1 |
20070233237 | Krivoruchko | Oct 2007 | A1 |
20070239272 | Navia et al. | Oct 2007 | A1 |
20070239273 | Allen | Oct 2007 | A1 |
20070244546 | Francis | Oct 2007 | A1 |
20070255400 | Parravicini et al. | Nov 2007 | A1 |
20080004688 | Spenser et al. | Jan 2008 | A1 |
20080004697 | Lichtenstein et al. | Jan 2008 | A1 |
20080051703 | Thornton et al. | Feb 2008 | A1 |
20080065204 | Macoviak et al. | Mar 2008 | A1 |
20080071361 | Tuval et al. | Mar 2008 | A1 |
20080071363 | Tuval et al. | Mar 2008 | A1 |
20080071366 | Tuval et al. | Mar 2008 | A1 |
20080071369 | Tuval et al. | Mar 2008 | A1 |
20080077235 | Kirson | Mar 2008 | A1 |
20080082083 | Forde et al. | Apr 2008 | A1 |
20080082159 | Tseng et al. | Apr 2008 | A1 |
20080082166 | Styrc et al. | Apr 2008 | A1 |
20080086204 | Rankin | Apr 2008 | A1 |
20080091261 | Long et al. | Apr 2008 | A1 |
20080097595 | Gabbay | Apr 2008 | A1 |
20080132989 | Snow et al. | Jun 2008 | A1 |
20080140003 | Bei et al. | Jun 2008 | A1 |
20080147182 | Righini et al. | Jun 2008 | A1 |
20080161910 | Revuelta et al. | Jul 2008 | A1 |
20080167705 | Agnew | Jul 2008 | A1 |
20080167714 | St. Goar et al. | Jul 2008 | A1 |
20080188929 | Schreck | Aug 2008 | A1 |
20080195200 | Vidlund et al. | Aug 2008 | A1 |
20080200980 | Robin et al. | Aug 2008 | A1 |
20080208328 | Antocci et al. | Aug 2008 | A1 |
20080208332 | Lamphere et al. | Aug 2008 | A1 |
20080221672 | Lamphere et al. | Sep 2008 | A1 |
20080234814 | Salahieh et al. | Sep 2008 | A1 |
20080243245 | Thambar et al. | Oct 2008 | A1 |
20080255580 | Hoffman et al. | Oct 2008 | A1 |
20080262609 | Gross et al. | Oct 2008 | A1 |
20080269879 | Sathe et al. | Oct 2008 | A1 |
20080281411 | Berreklouw | Nov 2008 | A1 |
20080294234 | Hartley et al. | Nov 2008 | A1 |
20090005863 | Goetz | Jan 2009 | A1 |
20090036966 | O'Connor et al. | Feb 2009 | A1 |
20090054969 | Salahieh et al. | Feb 2009 | A1 |
20090082844 | Zacharias et al. | Mar 2009 | A1 |
20090088836 | Bishop et al. | Apr 2009 | A1 |
20090099554 | Forster et al. | Apr 2009 | A1 |
20090099650 | Bolduc et al. | Apr 2009 | A1 |
20090112159 | Slattery et al. | Apr 2009 | A1 |
20090125098 | Chuter | May 2009 | A1 |
20090157175 | Benichou | Jun 2009 | A1 |
20090163934 | Raschdorf, Jr. et al. | Jun 2009 | A1 |
20090171363 | Chocron | Jul 2009 | A1 |
20090177278 | Spence | Jul 2009 | A1 |
20090210052 | Forster et al. | Aug 2009 | A1 |
20090222081 | Linder et al. | Sep 2009 | A1 |
20090240320 | Tuval et al. | Sep 2009 | A1 |
20090241656 | Jacquemin | Oct 2009 | A1 |
20090259306 | Rowe | Oct 2009 | A1 |
20090264859 | Mas | Oct 2009 | A1 |
20090264994 | Saadat | Oct 2009 | A1 |
20090276040 | Rowe et al. | Nov 2009 | A1 |
20090281619 | Le et al. | Nov 2009 | A1 |
20090287304 | Dahlgren et al. | Nov 2009 | A1 |
20090299449 | Styrc | Dec 2009 | A1 |
20090306768 | Quardi | Dec 2009 | A1 |
20090319037 | Rowe et al. | Dec 2009 | A1 |
20100022823 | Goldfarb | Jan 2010 | A1 |
20100023117 | Yoganathan et al. | Jan 2010 | A1 |
20100023120 | Holecek et al. | Jan 2010 | A1 |
20100036479 | Hill et al. | Feb 2010 | A1 |
20100049313 | Alon et al. | Feb 2010 | A1 |
20100069852 | Kelley | Mar 2010 | A1 |
20100076548 | Konno | Mar 2010 | A1 |
20100100167 | Bortlein et al. | Apr 2010 | A1 |
20100114299 | Ben-Muvhar et al. | May 2010 | A1 |
20100131054 | Tuval et al. | May 2010 | A1 |
20100137979 | Tuval et al. | Jun 2010 | A1 |
20100160958 | Clark | Jun 2010 | A1 |
20100161036 | Pintor | Jun 2010 | A1 |
20100161042 | Maisano et al. | Jun 2010 | A1 |
20100174363 | Castro | Jul 2010 | A1 |
20100179643 | Shalev | Jul 2010 | A1 |
20100179648 | Richter et al. | Jul 2010 | A1 |
20100179649 | Richter et al. | Jul 2010 | A1 |
20100185277 | Braido et al. | Jul 2010 | A1 |
20100217382 | Chau et al. | Aug 2010 | A1 |
20100222810 | DeBeer et al. | Sep 2010 | A1 |
20100228285 | Miles et al. | Sep 2010 | A1 |
20100234940 | Dolan | Sep 2010 | A1 |
20100249908 | Chau et al. | Sep 2010 | A1 |
20100249917 | Zhang | Sep 2010 | A1 |
20100256737 | Pollock et al. | Oct 2010 | A1 |
20100262232 | Annest | Oct 2010 | A1 |
20100280603 | Maisano et al. | Nov 2010 | A1 |
20100280606 | Naor | Nov 2010 | A1 |
20100312333 | Navia et al. | Dec 2010 | A1 |
20100324595 | Linder et al. | Dec 2010 | A1 |
20100331971 | Keranen et al. | Dec 2010 | A1 |
20110004227 | Goldfarb et al. | Jan 2011 | A1 |
20110004296 | Lutter et al. | Jan 2011 | A1 |
20110004299 | Navia et al. | Jan 2011 | A1 |
20110015729 | Jimenez et al. | Jan 2011 | A1 |
20110015731 | Carpentier et al. | Jan 2011 | A1 |
20110015739 | Cheung et al. | Jan 2011 | A1 |
20110021985 | Spargias | Jan 2011 | A1 |
20110022165 | Oba et al. | Jan 2011 | A1 |
20110178597 | Navia et al. | Jan 2011 | A9 |
20110029067 | Mcguckin, Jr. et al. | Feb 2011 | A1 |
20110029072 | Gabbay | Feb 2011 | A1 |
20110040374 | Goetz et al. | Feb 2011 | A1 |
20110040375 | Letac et al. | Feb 2011 | A1 |
20110046662 | Moszner et al. | Feb 2011 | A1 |
20110054466 | Rothstein et al. | Mar 2011 | A1 |
20110054596 | Taylor | Mar 2011 | A1 |
20110054598 | Johnson | Mar 2011 | A1 |
20110066233 | Thornton et al. | Mar 2011 | A1 |
20110071626 | Wright et al. | Mar 2011 | A1 |
20110077730 | Fentster | Mar 2011 | A1 |
20110082538 | Dahlgren et al. | Apr 2011 | A1 |
20110087322 | Letac et al. | Apr 2011 | A1 |
20110093063 | Schreck | Apr 2011 | A1 |
20110098525 | Kermode et al. | Apr 2011 | A1 |
20110106247 | Miller et al. | May 2011 | A1 |
20110112625 | Ben-Muvhar et al. | May 2011 | A1 |
20110112632 | Chau et al. | May 2011 | A1 |
20110113768 | Bauer et al. | May 2011 | A1 |
20110118830 | Liddicoat et al. | May 2011 | A1 |
20110125257 | Seguin et al. | May 2011 | A1 |
20110125258 | Centola | May 2011 | A1 |
20110137326 | Bachman | Jun 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110137409 | Yang et al. | Jun 2011 | A1 |
20110137410 | Hacohen | Jun 2011 | A1 |
20110144742 | Madrid et al. | Jun 2011 | A1 |
20110166636 | Rowe | Jul 2011 | A1 |
20110172784 | Richter | Jul 2011 | A1 |
20110184510 | Maisano et al. | Jul 2011 | A1 |
20110190877 | Lane et al. | Aug 2011 | A1 |
20110190879 | Bobo et al. | Aug 2011 | A1 |
20110202076 | Richter | Aug 2011 | A1 |
20110208283 | Rust | Aug 2011 | A1 |
20110208293 | Tabor | Aug 2011 | A1 |
20110208298 | Tuval et al. | Aug 2011 | A1 |
20110213459 | Garrison et al. | Sep 2011 | A1 |
20110213461 | Seguin et al. | Sep 2011 | A1 |
20110218619 | Benichou et al. | Sep 2011 | A1 |
20110218620 | Meiri et al. | Sep 2011 | A1 |
20110224785 | Hacohen | Sep 2011 | A1 |
20110238159 | Guyenot et al. | Sep 2011 | A1 |
20110245911 | Quill et al. | Oct 2011 | A1 |
20110245917 | Savage et al. | Oct 2011 | A1 |
20110251675 | Dwork | Oct 2011 | A1 |
20110251676 | Sweeney et al. | Oct 2011 | A1 |
20110251678 | Eidenschink et al. | Oct 2011 | A1 |
20110251679 | Weimeyer et al. | Oct 2011 | A1 |
20110251680 | Tran et al. | Oct 2011 | A1 |
20110251682 | Murray, III et al. | Oct 2011 | A1 |
20110251683 | Tabor | Oct 2011 | A1 |
20110257721 | Tabor | Oct 2011 | A1 |
20110257729 | Spenser et al. | Oct 2011 | A1 |
20110257736 | Marquez et al. | Oct 2011 | A1 |
20110257737 | Fogarty et al. | Oct 2011 | A1 |
20110264191 | Rothstein | Oct 2011 | A1 |
20110264196 | Savage et al. | Oct 2011 | A1 |
20110264198 | Murray, III et al. | Oct 2011 | A1 |
20110264199 | Tran et al. | Oct 2011 | A1 |
20110264200 | Tran et al. | Oct 2011 | A1 |
20110264201 | Yeung | Oct 2011 | A1 |
20110264202 | Murray, III et al. | Oct 2011 | A1 |
20110264203 | Dwork et al. | Oct 2011 | A1 |
20110264206 | Tabor | Oct 2011 | A1 |
20110264208 | Duffy | Oct 2011 | A1 |
20110270276 | Rothstein et al. | Nov 2011 | A1 |
20110271967 | Mortier et al. | Nov 2011 | A1 |
20110282438 | Drews et al. | Nov 2011 | A1 |
20110282439 | Thill | Nov 2011 | A1 |
20110282440 | Cao | Nov 2011 | A1 |
20110283514 | Fogarty et al. | Nov 2011 | A1 |
20110288632 | White | Nov 2011 | A1 |
20110288634 | Tuval et al. | Nov 2011 | A1 |
20110295354 | Bueche et al. | Dec 2011 | A1 |
20110295363 | Girard et al. | Dec 2011 | A1 |
20110301688 | Dolan | Dec 2011 | A1 |
20110301698 | Miller et al. | Dec 2011 | A1 |
20110301701 | Padala et al. | Dec 2011 | A1 |
20110301702 | Rust et al. | Dec 2011 | A1 |
20110306916 | Nitzan et al. | Dec 2011 | A1 |
20110307049 | Kao | Dec 2011 | A1 |
20110313452 | Carley et al. | Dec 2011 | A1 |
20110313515 | Quadri et al. | Dec 2011 | A1 |
20110319989 | Lane | Dec 2011 | A1 |
20110319991 | Hariton et al. | Dec 2011 | A1 |
20120010694 | Lutter et al. | Jan 2012 | A1 |
20120016468 | Robin et al. | Jan 2012 | A1 |
20120022629 | Perera et al. | Jan 2012 | A1 |
20120022633 | Olson et al. | Jan 2012 | A1 |
20120022637 | Ben-Movhar et al. | Jan 2012 | A1 |
20120022639 | Hacohen et al. | Jan 2012 | A1 |
20120022640 | Gross et al. | Jan 2012 | A1 |
20120035703 | Lutter et al. | Feb 2012 | A1 |
20120035713 | Lutter et al. | Feb 2012 | A1 |
20120035722 | Tuval et al. | Feb 2012 | A1 |
20120041547 | Duffy et al. | Feb 2012 | A1 |
20120041551 | Spenser et al. | Feb 2012 | A1 |
20120046738 | Lau et al. | Feb 2012 | A1 |
20120046742 | Tuval et al. | Feb 2012 | A1 |
20120053676 | Ku et al. | Mar 2012 | A1 |
20120053680 | Bolling et al. | Mar 2012 | A1 |
20120053682 | Kovalsky et al. | Mar 2012 | A1 |
20120053688 | Fogarty et al. | Mar 2012 | A1 |
20120059454 | Millwee et al. | Mar 2012 | A1 |
20120059458 | Buchbinder et al. | Mar 2012 | A1 |
20120065464 | Ellis et al. | Mar 2012 | A1 |
20120078237 | Wang et al. | Mar 2012 | A1 |
20120078353 | Quadri et al. | Mar 2012 | A1 |
20120078357 | Conklin | Mar 2012 | A1 |
20120083832 | Delaloye et al. | Apr 2012 | A1 |
20120083839 | Letac et al. | Apr 2012 | A1 |
20120083879 | Eberhardt et al. | Apr 2012 | A1 |
20120089223 | Nguyen et al. | Apr 2012 | A1 |
20120101570 | Tuval et al. | Apr 2012 | A1 |
20120101571 | Thambar et al. | Apr 2012 | A1 |
20120101572 | Kovalsky et al. | Apr 2012 | A1 |
20120123511 | Brown | May 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120123530 | Carpentier et al. | May 2012 | A1 |
20120130473 | Norris et al. | May 2012 | A1 |
20120130474 | Buckley | May 2012 | A1 |
20120130475 | Shaw | May 2012 | A1 |
20120136434 | Carpentier et al. | May 2012 | A1 |
20120150218 | Sandgren et al. | Jun 2012 | A1 |
20120165915 | Melsheimer et al. | Jun 2012 | A1 |
20120165930 | Gifford, III et al. | Jun 2012 | A1 |
20120179244 | Schankereli et al. | Jul 2012 | A1 |
20120197292 | Chin-Chen et al. | Aug 2012 | A1 |
20120283824 | Lutter et al. | Nov 2012 | A1 |
20120290062 | McNamara et al. | Nov 2012 | A1 |
20120296360 | Norris et al. | Nov 2012 | A1 |
20120296418 | Bonyuet et al. | Nov 2012 | A1 |
20120300063 | Majkrzak et al. | Nov 2012 | A1 |
20120310328 | Olson et al. | Dec 2012 | A1 |
20120323316 | Chau et al. | Dec 2012 | A1 |
20120330408 | Hillukka et al. | Dec 2012 | A1 |
20130006347 | McHugo | Jan 2013 | A1 |
20130018450 | Hunt | Jan 2013 | A1 |
20130018458 | Yohanan et al. | Jan 2013 | A1 |
20130030519 | Tran et al. | Jan 2013 | A1 |
20130035759 | Gross et al. | Feb 2013 | A1 |
20130041451 | Patterson et al. | Feb 2013 | A1 |
20130046373 | Cartledge et al. | Feb 2013 | A1 |
20130066341 | Ketai et al. | Mar 2013 | A1 |
20130066342 | Dell | Mar 2013 | A1 |
20130079872 | Gallagher | Mar 2013 | A1 |
20130116780 | Miller et al. | May 2013 | A1 |
20130123896 | Bloss et al. | May 2013 | A1 |
20130123900 | Eblacas et al. | May 2013 | A1 |
20130150945 | Crawford et al. | Jun 2013 | A1 |
20130150956 | Yohanan et al. | Jun 2013 | A1 |
20130158647 | Norris et al. | Jun 2013 | A1 |
20130165930 | Lehmann | Jun 2013 | A1 |
20130166017 | Cartledge et al. | Jun 2013 | A1 |
20130166022 | Conklin | Jun 2013 | A1 |
20130172978 | Vidlund et al. | Jul 2013 | A1 |
20130172992 | Gross et al. | Jul 2013 | A1 |
20130190861 | Chau et al. | Jul 2013 | A1 |
20130211501 | Buckley et al. | Aug 2013 | A1 |
20130245742 | Norris | Sep 2013 | A1 |
20130253543 | Rolando et al. | Sep 2013 | A1 |
20130253643 | Rolando et al. | Sep 2013 | A1 |
20130261737 | Costello | Oct 2013 | A1 |
20130261738 | Clague et al. | Oct 2013 | A1 |
20130274870 | Lombardi et al. | Oct 2013 | A1 |
20130282059 | Ketai et al. | Oct 2013 | A1 |
20130289711 | Liddy et al. | Oct 2013 | A1 |
20130289740 | Liddy et al. | Oct 2013 | A1 |
20130297013 | Klima et al. | Nov 2013 | A1 |
20130304197 | Buchbinder et al. | Nov 2013 | A1 |
20130304200 | McLean et al. | Nov 2013 | A1 |
20130310928 | Morriss et al. | Nov 2013 | A1 |
20130325114 | McLean et al. | Dec 2013 | A1 |
20130331929 | Mitra et al. | Dec 2013 | A1 |
20140000112 | Braido et al. | Jan 2014 | A1 |
20140005778 | Buchbinder et al. | Jan 2014 | A1 |
20140018911 | Zhou et al. | Jan 2014 | A1 |
20140018915 | Biadillah et al. | Jan 2014 | A1 |
20140031928 | Murphy et al. | Jan 2014 | A1 |
20140046430 | Shaw | Feb 2014 | A1 |
20140052237 | Lane et al. | Feb 2014 | A1 |
20140067050 | Costello et al. | Mar 2014 | A1 |
20140067054 | Chau | Mar 2014 | A1 |
20140081376 | Burkart et al. | Mar 2014 | A1 |
20140106951 | Brandon | Apr 2014 | A1 |
20140120287 | Jacoby et al. | May 2014 | A1 |
20140121749 | Roeder | May 2014 | A1 |
20140121763 | Duffy et al. | May 2014 | A1 |
20140135894 | Norris et al. | May 2014 | A1 |
20140135895 | Andress et al. | May 2014 | A1 |
20140142681 | Norris | May 2014 | A1 |
20140142688 | Duffy et al. | May 2014 | A1 |
20140148891 | Johnson | May 2014 | A1 |
20140163690 | White | Jun 2014 | A1 |
20140172069 | Roeder et al. | Jun 2014 | A1 |
20140172077 | Bruchman et al. | Jun 2014 | A1 |
20140172082 | Bruchman et al. | Jun 2014 | A1 |
20140188210 | Beard et al. | Jul 2014 | A1 |
20140188221 | Chung et al. | Jul 2014 | A1 |
20140194981 | Menk et al. | Jul 2014 | A1 |
20140194983 | Kovalsky et al. | Jul 2014 | A1 |
20140207231 | Hacohen | Jul 2014 | A1 |
20140214157 | Börtlein et al. | Jul 2014 | A1 |
20140214159 | Vidlund et al. | Jul 2014 | A1 |
20140222136 | Geist et al. | Aug 2014 | A1 |
20140222142 | Kovalsky et al. | Aug 2014 | A1 |
20140236287 | Clague et al. | Aug 2014 | A1 |
20140236289 | Alkhatib | Aug 2014 | A1 |
20140249622 | Carmi et al. | Sep 2014 | A1 |
20140257461 | Robinson et al. | Sep 2014 | A1 |
20140257467 | Lane | Sep 2014 | A1 |
20140257475 | Gross et al. | Sep 2014 | A1 |
20140257476 | Montorfano et al. | Sep 2014 | A1 |
20140277358 | Slazas | Sep 2014 | A1 |
20140277409 | Bortlein et al. | Sep 2014 | A1 |
20140277411 | Börtlein et al. | Sep 2014 | A1 |
20140277412 | Börtlein et al. | Sep 2014 | A1 |
20140277418 | Miller | Sep 2014 | A1 |
20140277422 | Ratz et al. | Sep 2014 | A1 |
20140277427 | Ratz et al. | Sep 2014 | A1 |
20140296962 | Cartledge et al. | Oct 2014 | A1 |
20140296969 | Tegels et al. | Oct 2014 | A1 |
20140324164 | Gross et al. | Oct 2014 | A1 |
20140331475 | Duffy et al. | Nov 2014 | A1 |
20140336744 | Tani et al. | Nov 2014 | A1 |
20140343670 | Bakis et al. | Nov 2014 | A1 |
20140350662 | Vaturi | Nov 2014 | A1 |
20140350670 | Keränen | Nov 2014 | A1 |
20140358222 | Gorman, III et al. | Dec 2014 | A1 |
20140358224 | Tegels et al. | Dec 2014 | A1 |
20140379065 | Johnson et al. | Dec 2014 | A1 |
20140379074 | Spence et al. | Dec 2014 | A1 |
20140379076 | Vidlund et al. | Dec 2014 | A1 |
20150018944 | O'Connor et al. | Jan 2015 | A1 |
20150032205 | Matheny | Jan 2015 | A1 |
20150045880 | Hacohen | Feb 2015 | A1 |
20150045881 | Lim | Feb 2015 | A1 |
20150094802 | Buchbinder et al. | Apr 2015 | A1 |
20150119970 | Nakayama et al. | Apr 2015 | A1 |
20150127097 | Neumann et al. | May 2015 | A1 |
20150142100 | Morriss et al. | May 2015 | A1 |
20150142103 | Vidlund | May 2015 | A1 |
20150157457 | Hacohen | Jun 2015 | A1 |
20150157458 | Thambar et al. | Jun 2015 | A1 |
20150164640 | McLean et al. | Jun 2015 | A1 |
20150173896 | Richter | Jun 2015 | A1 |
20150173897 | Raanani et al. | Jun 2015 | A1 |
20150196390 | Ma et al. | Jul 2015 | A1 |
20150196393 | Vidlund et al. | Jul 2015 | A1 |
20150216661 | Hacohen et al. | Aug 2015 | A1 |
20150238313 | Spence et al. | Aug 2015 | A1 |
20150245934 | Lombardi et al. | Sep 2015 | A1 |
20150272730 | Melnick | Oct 2015 | A1 |
20150272731 | Racchini et al. | Oct 2015 | A1 |
20150272734 | Sheps et al. | Oct 2015 | A1 |
20150282964 | Beard et al. | Oct 2015 | A1 |
20150320556 | Levi et al. | Nov 2015 | A1 |
20150327994 | Morriss | Nov 2015 | A1 |
20150328000 | Ratz et al. | Nov 2015 | A1 |
20150335429 | Morriss et al. | Nov 2015 | A1 |
20150342736 | Rabito et al. | Dec 2015 | A1 |
20150351903 | Morriss et al. | Dec 2015 | A1 |
20150351904 | Cooper et al. | Dec 2015 | A1 |
20150351906 | Hammer et al. | Dec 2015 | A1 |
20150359629 | Ganesan et al. | Dec 2015 | A1 |
20160008129 | Siegel | Jan 2016 | A1 |
20160030169 | Shahriari | Feb 2016 | A1 |
20160030171 | Quijano et al. | Feb 2016 | A1 |
20160089482 | Siegenthaler | Mar 2016 | A1 |
20160095700 | Righini | Apr 2016 | A1 |
20160100939 | Armstrong et al. | Apr 2016 | A1 |
20160106539 | Buchbinder et al. | Apr 2016 | A1 |
20160113766 | Ganesan et al. | Apr 2016 | A1 |
20160113768 | Ganesan et al. | Apr 2016 | A1 |
20160125160 | Heneghan et al. | May 2016 | A1 |
20160157862 | Hernandez et al. | Jun 2016 | A1 |
20160175095 | Dienno et al. | Jun 2016 | A1 |
20160213473 | Hacohen et al. | Jul 2016 | A1 |
20160220367 | Barrett | Aug 2016 | A1 |
20160228247 | Maimon et al. | Aug 2016 | A1 |
20160242902 | Morriss et al. | Aug 2016 | A1 |
20160270911 | Ganesan et al. | Sep 2016 | A1 |
20160296330 | Hacohen | Oct 2016 | A1 |
20160310268 | Oba et al. | Oct 2016 | A1 |
20160310274 | Gross et al. | Oct 2016 | A1 |
20160317301 | Quadri et al. | Nov 2016 | A1 |
20160317305 | Pelled et al. | Nov 2016 | A1 |
20160324633 | Gross et al. | Nov 2016 | A1 |
20160324635 | Vidlund et al. | Nov 2016 | A1 |
20160324640 | Gifford et al. | Nov 2016 | A1 |
20160331526 | Schweich et al. | Nov 2016 | A1 |
20160331527 | Vidlund et al. | Nov 2016 | A1 |
20160338706 | Rowe | Nov 2016 | A1 |
20160367360 | Cartledge et al. | Dec 2016 | A1 |
20160367368 | Vidlund et al. | Dec 2016 | A1 |
20160374801 | Jimenez et al. | Dec 2016 | A1 |
20160374802 | Levi et al. | Dec 2016 | A1 |
20170042678 | Ganesan et al. | Feb 2017 | A1 |
20170049435 | Sauer et al. | Feb 2017 | A1 |
20170056166 | Ratz et al. | Mar 2017 | A1 |
20170056171 | Cooper et al. | Mar 2017 | A1 |
20170065407 | Hacohen et al. | Mar 2017 | A1 |
20170065411 | Grundeman et al. | Mar 2017 | A1 |
20170100236 | Robertson et al. | Apr 2017 | A1 |
20170128205 | Tamir et al. | May 2017 | A1 |
20170135816 | Lashinski et al. | May 2017 | A1 |
20170189174 | Braido et al. | Jul 2017 | A1 |
20170196688 | Christianson et al. | Jul 2017 | A1 |
20170196692 | Kirk et al. | Jul 2017 | A1 |
20170209264 | Chau et al. | Jul 2017 | A1 |
20170216026 | Quill et al. | Aug 2017 | A1 |
20170224323 | Rowe et al. | Aug 2017 | A1 |
20170231757 | Gassler | Aug 2017 | A1 |
20170231759 | Geist et al. | Aug 2017 | A1 |
20170231760 | Lane et al. | Aug 2017 | A1 |
20170231766 | Hariton et al. | Aug 2017 | A1 |
20170239048 | Goldfarb et al. | Aug 2017 | A1 |
20170252159 | Hacohen et al. | Sep 2017 | A1 |
20170266003 | Hammer et al. | Sep 2017 | A1 |
20170333183 | Backus | Nov 2017 | A1 |
20170333187 | Hariton et al. | Nov 2017 | A1 |
20170360426 | Hacohen et al. | Dec 2017 | A1 |
20170367823 | Hariton et al. | Dec 2017 | A1 |
20180000580 | Wallace et al. | Jan 2018 | A1 |
20180014930 | Hariton et al. | Jan 2018 | A1 |
20180014932 | Hammer et al. | Jan 2018 | A1 |
20180021129 | Peterson et al. | Jan 2018 | A1 |
20180028215 | Cohen | Feb 2018 | A1 |
20180049873 | Manash et al. | Feb 2018 | A1 |
20180055628 | Patel et al. | Mar 2018 | A1 |
20180055630 | Patel et al. | Mar 2018 | A1 |
20180098850 | Rafiee et al. | Apr 2018 | A1 |
20180116790 | Ratz et al. | May 2018 | A1 |
20180132999 | Perouse | May 2018 | A1 |
20180147059 | Hammer et al. | May 2018 | A1 |
20180153687 | Hariton et al. | Jun 2018 | A1 |
20180153689 | Maimon et al. | Jun 2018 | A1 |
20180161159 | Lee et al. | Jun 2018 | A1 |
20180177594 | Patel et al. | Jun 2018 | A1 |
20180206983 | Noe et al. | Jul 2018 | A1 |
20180214263 | Rolando et al. | Aug 2018 | A1 |
20180243086 | Barbarino et al. | Aug 2018 | A1 |
20180250126 | O'connor et al. | Sep 2018 | A1 |
20180250147 | Syed | Sep 2018 | A1 |
20180296333 | Dixon et al. | Oct 2018 | A1 |
20180296336 | Cooper et al. | Oct 2018 | A1 |
20180296341 | Noe et al. | Oct 2018 | A1 |
20180325671 | Abunassar et al. | Nov 2018 | A1 |
20180344457 | Gross et al. | Dec 2018 | A1 |
20180344490 | Fox et al. | Dec 2018 | A1 |
20180353294 | Calomeni et al. | Dec 2018 | A1 |
20180360457 | Ellis et al. | Dec 2018 | A1 |
20190000613 | Delgado et al. | Jan 2019 | A1 |
20190015200 | Delgado et al. | Jan 2019 | A1 |
20190021852 | Delgado et al. | Jan 2019 | A1 |
20190021857 | Hacohen et al. | Jan 2019 | A1 |
20190053896 | Adamek-bowers et al. | Feb 2019 | A1 |
20190060060 | Chau et al. | Feb 2019 | A1 |
20190060068 | Cope et al. | Feb 2019 | A1 |
20190060070 | Groothuis et al. | Feb 2019 | A1 |
20190069997 | Ratz et al. | Mar 2019 | A1 |
20190083261 | Perszyk et al. | Mar 2019 | A1 |
20190105153 | Barash et al. | Apr 2019 | A1 |
20190117391 | Humair | Apr 2019 | A1 |
20190167423 | Hariton et al. | Jun 2019 | A1 |
20190175339 | Vidlund | Jun 2019 | A1 |
20190175342 | Hariton et al. | Jun 2019 | A1 |
20190183639 | Moore | Jun 2019 | A1 |
20190183644 | Hacohen | Jun 2019 | A1 |
20190192295 | Spence et al. | Jun 2019 | A1 |
20190216602 | Lozonschi | Jul 2019 | A1 |
20190321172 | Gross et al. | Oct 2019 | A1 |
20190336280 | Naor | Nov 2019 | A1 |
20190350701 | Adamek-bowers et al. | Nov 2019 | A1 |
20190365530 | Hoang et al. | Dec 2019 | A1 |
20190388218 | Vidlund et al. | Dec 2019 | A1 |
20190388220 | Vidlund et al. | Dec 2019 | A1 |
20200000449 | Goldfarb et al. | Jan 2020 | A1 |
20200000579 | Manash et al. | Jan 2020 | A1 |
20200015964 | Noe et al. | Jan 2020 | A1 |
20200060818 | Geist et al. | Feb 2020 | A1 |
20200078002 | Hacohen et al. | Mar 2020 | A1 |
20200163761 | Hariton et al. | May 2020 | A1 |
20200246140 | Hariton et al. | Aug 2020 | A1 |
20200261094 | Goldfarb et al. | Aug 2020 | A1 |
20200330221 | Hacohen | Oct 2020 | A1 |
20200330227 | Hacohen | Oct 2020 | A1 |
20210093449 | Hariton et al. | Apr 2021 | A1 |
20210106419 | Abunassar | Apr 2021 | A1 |
20210113331 | Quadri et al. | Apr 2021 | A1 |
20210137680 | Kizuka et al. | May 2021 | A1 |
20210259835 | Tyler, II et al. | Aug 2021 | A1 |
20220000612 | Hacohen | Jan 2022 | A1 |
Number | Date | Country |
---|---|---|
2822801 | Aug 2006 | CA |
103974674 | Aug 2014 | CN |
0170262 | Feb 1986 | EP |
1264582 | Dec 2002 | EP |
1768630 | Jan 2015 | EP |
2739214 | Oct 2018 | EP |
3417813 | Dec 2018 | EP |
S53152790 | Dec 1978 | JP |
20010046894 | Jun 2001 | KR |
1998043557 | Oct 1998 | WO |
1999030647 | Jun 1999 | WO |
2000047139 | Aug 2000 | WO |
2001062189 | Aug 2001 | WO |
0182832 | Nov 2001 | WO |
2003020179 | Mar 2003 | WO |
2003028558 | Apr 2003 | WO |
2004108191 | Dec 2004 | WO |
2005107650 | Nov 2005 | WO |
2006007401 | Jan 2006 | WO |
06054930 | May 2006 | WO |
2006070372 | Jul 2006 | WO |
2006086434 | Aug 2006 | WO |
2006089236 | Aug 2006 | WO |
2006116558 | Nov 2006 | WO |
2006128193 | Nov 2006 | WO |
2007059252 | May 2007 | WO |
08013915 | Jan 2008 | WO |
2008029296 | Mar 2008 | WO |
2008070797 | Jun 2008 | WO |
2008103722 | Aug 2008 | WO |
09033469 | Mar 2009 | WO |
09053497 | Apr 2009 | WO |
2009091509 | Jul 2009 | WO |
2010005827 | Jan 2010 | WO |
2010006627 | Jan 2010 | WO |
2010037141 | Apr 2010 | WO |
2010045297 | Apr 2010 | WO |
2010057262 | May 2010 | WO |
2010073246 | Jul 2010 | WO |
2010081033 | Jul 2010 | WO |
2010121076 | Oct 2010 | WO |
2011025972 | Mar 2011 | WO |
2011069048 | Jun 2011 | WO |
2011089601 | Jul 2011 | WO |
2011106137 | Sep 2011 | WO |
2011111047 | Sep 2011 | WO |
0187190 | Nov 2011 | WO |
2011137531 | Nov 2011 | WO |
2011143263 | Nov 2011 | WO |
2011154942 | Dec 2011 | WO |
2012011108 | Jan 2012 | WO |
2012024428 | Feb 2012 | WO |
2012036740 | Mar 2012 | WO |
2012048035 | Apr 2012 | WO |
2012127309 | Sep 2012 | WO |
2012177942 | Dec 2012 | WO |
2013021374 | Feb 2013 | WO |
2013021375 | Feb 2013 | WO |
2013021384 | Feb 2013 | WO |
2013059747 | Apr 2013 | WO |
2013072496 | May 2013 | WO |
2013078497 | Jun 2013 | WO |
2013114214 | Aug 2013 | WO |
2013128436 | Sep 2013 | WO |
2013175468 | Nov 2013 | WO |
2014022124 | Feb 2014 | WO |
2014076696 | May 2014 | WO |
2014115149 | Jul 2014 | WO |
2014121280 | Aug 2014 | WO |
2014145338 | Sep 2014 | WO |
2014164364 | Oct 2014 | WO |
2014194178 | Dec 2014 | WO |
2015173794 | Nov 2015 | WO |
2015191923 | Dec 2015 | WO |
2016016899 | Feb 2016 | WO |
2016093877 | Jun 2016 | WO |
2016125160 | Aug 2016 | WO |
2017223486 | Dec 2017 | WO |
2018025260 | Feb 2018 | WO |
2018025263 | Feb 2018 | WO |
2018029680 | Feb 2018 | WO |
2018039631 | Mar 2018 | WO |
2018106837 | Jun 2018 | WO |
2018112429 | Jun 2018 | WO |
2018118717 | Jun 2018 | WO |
2018131042 | Jul 2018 | WO |
2018131043 | Jul 2018 | WO |
2019026059 | Feb 2019 | WO |
2019030753 | Feb 2019 | WO |
2019027507 | Feb 2019 | WO |
2019077595 | Apr 2019 | WO |
2019116369 | Jun 2019 | WO |
2019138400 | Jul 2019 | WO |
2019195860 | Oct 2019 | WO |
2019202579 | Oct 2019 | WO |
2020058972 | Mar 2020 | WO |
2021156866 | Aug 2021 | WO |
2021186424 | Sep 2021 | WO |
Entry |
---|
An Office Action dated Nov. 23, 2012, which issued during the prosecution of U.S. Appl. No. 13/033,852. |
An Office Action dated Dec. 31, 2012, which issued during the prosecution of U.S. Appl. No. 13/044,694. |
An Office Action dated Feb. 6, 2013, which, issued during the prosecution of U.S. Appl. No. 13/412,814. |
Langer F et al., “Ring plus String: 'Papillary muscle repositioning as an adjunctive repair technique for ischemic mitral regurgitation,” J Thorac Cardiovasc Surg 133:247-9, Jan. 2007. |
Langer F et al., “Ring+String: Successful repair technique for ischemic mitral regurgitation with severe leaflet tethering,” Circulation 120[suppl 1 ]: S85-S91, Sep. 2009. |
“Transcatheter Valve-in-Valve Implantation for Failed Bioprosthetic Heart Valves”, J Webb et al., Circulation. Apr. 2010; 121: 1848-1857. |
Jansen, J., Willeke, S., Reul, H. and Rum, G. (1992), Detachable Shape-Memory Sewing Ring for Heart Valves. Artificial Organs, 16:294-297,1992 (an abstract). |
Alexander S. Geha, et al., Replacement of degenerated mitral and aortic bioprostheses without explanation Ann Thorac Surg. Jun. 2001; 72:1509-1514. |
An International Search Report and a Written Opinion both dated Oct. 13, 2011 which issued during the prosecution of Applicant's PCT/IL11/00231. |
An Office Action dated Jul. 1, 2016, which issued during the prosecution of U.S. Appl. No. 14/161,921. |
An International Search Report and a Written Opinion both dated Dec. 5, 2011, which issued during the prosecution of Applicant's PCT/IL11/00582. |
An Office Action dated May 29, 2012, which issued during the prosecution of U.S. Appl. No. 12/840,463. |
U.S. Appl. No. 61/555,160, filed Nov. 3, 2011. |
U.S. Appl. No. 61/525,281, filed Aug. 19, 2011. |
U.S. Appl. No. 61/537,276, filed Sep. 21, 2011. |
U.S. Appl. No. 61/515,372, filed Aug. 5, 2011. |
U.S. Appl. No. 61/492,449, filed Jun. 2, 2011. |
U.S. Appl. No. 61/588,892, filed Jan. 20, 2012. |
An International Search Report and a Written Opinion both dated Feb. 6, 2013, which issued during the prosecution of Applicant's PCT/IL12/00292. |
An International Search Report and a Written Opinion both dated Feb. 6, 2013, which issued during the prosecution of Applicant's PCT/IL12/00293. |
An Office Action dated Nov. 28, 2012, which issued during the prosecution of U.S. Appl. No. 12/961,721. |
An Office Action dated Feb. 15, 2013, which issued during the prosecution of U.S. Appl. No. 12/840,463. |
An Office Action dated Feb. 10, 2014, which issued during the prosecution of U.S. Appl. No. 13/033,852. |
An Office Action dated Sep. 19, 2014, which issued during the prosecution of U.S. Appl. No. 13/044,694. |
An International Search Report and a Written Opinion both dated Sep. 4, 2014 which issued during the prosecution of Applicant's PCT/IL2014/050087. |
Invitation to Pay Additional Fees dated Jun. 12, 2014 PCT/IL2014/050087. |
An Office Action dated Jun. 17, 2014, which issued during the prosecution of U.S. Appl. No. 12/961,721. |
An Office Action dated Jul. 3, 2014, which issued during the prosecution of U.S. Appl. No. 13/033,852. |
An Office Action dated May 23, 2014, which issued during the prosecution of U.S. Appl. No. 13/412,814. |
Dominique Himbert; Mitral Regurgitation and Stenosis from Bioprosthesis and Annuloplasty Failure: Transcatheter approaches and outcomes, 24 pages Oct. 28, 2013. |
An International Search Report and a Written Opinion both dated Mar. 17, 2014 which issued during the prosecution of Applicant's PCT/IL2013/050937. |
An International Preliminary Report on patentabilty dated Dec. 2, 2013, which issued daring the prosecution of Applicant's PCT/IL11/00582. |
An Office Action dated Sep. 12, 2013, which issued during the prosecution of U.S. Appl. No. 13/412,814. |
An Office Action dated Aug. 2, 2013, which issued during the prosecution of U.S. Appl. No. 13/033,852. |
An International Preliminary Report on patentabilty dated Sep. 11, 2012, which issued during the prosecution of Applicant's PCT/IL2011/000231. |
An Office Action dated Jul. 2, 2014, which issued during the prosecution of U.S. Appl. No. 13/811,308. |
An Office Action dated Jan. 20, 2016, which issued during the prosecution of U.S. Appl. No. 14/161,921. |
An Office Action dated Jul. 23, 2013, which issued during the prosecution of U.S. Appl. No. 12/961,721. |
An Office Action dated Jul. 18, 2013, which issued during the prosecution of U.S. Appl. No. 13/044,694. |
An Office Action dated Nov. 8, 2013, which issued during the prosecution of U.S. Appl. No. 12/840,463. |
An Office Action dated Jun. 4, 2014, which issued during the prosecution of U.S. Appl. No. U.S. Appl. No. 12/840,463. |
An Office Action dated Aug. 13, 2012, which issued dating the prosecution of U.S. Appl. No. 13/044,694. |
An Office Action dated Jul. 2, 2012, which issued during the prosecution of U.S. Appl. No. 13/033,852. |
An Office Action dated Feb. 3, 2014, which issued during the prosecution of U.S. Appl. No. 13/811,308. |
An International Preliminary Report on patentabilty dated Feb. 11, 2014, which issued during the prosecution of Applicant's PCT/IL12/00292. |
An International Preliminary Report on patentabilty dated Feb. 11, 2014, which issued during the prosecution of Applicant's PCT/IL12/00293. |
A Notice of Allowance dated Aug. 15, 2014. which issued during the prosecution of U.S. Appl. No. 13/412,814. |
An Office Action dated Aug. 14, 2012, which issued during the prosecution of U.S. Appl. No. 12/961,721. |
U.S. Appl. No. 61/283,819, filed Dec. 8, 2009. |
Notice of Allowance dated Apr. 8, 2016, which issued during the prosecution of U.S. Appl. No. 14/237,258. |
U.S. Appl. No. 61/756,034, filed Jan. 24, 2013. |
U.S. Appl. No. 61/756,049, filed Jan. 24, 2013. |
An International Preliminary Report on Patentability dated Jan. 31, 2017, which issued during the prosecution of Applicant's PCT/IL2015/050792. |
U.S. Appl. No. 61/312,412, filed Mar. 10, 2010. |
U.S. Appl. No. 62/139,854, filed Mar. 30, 2015. |
Notice of Allowance dated Apr. 20, 2018, which issued during the prosecution of U.S. Appl. No. 15/878,206. |
An Office Action dated Dec. 10, 2015, which issued during the prosecution of U.S. Appl. No. 14/237,258. |
An International Preliminary Report on Patentability dated Jul. 28, 2015, which issued during the prosecution of Applicant's PCT/IL2014/050087. |
An Office Action dated Nov. 27, 2015, which issued during the prosecution of U.S. Appl. No. 14/626,267. |
An Office Action dated Jan. 21, 2016, which issued during the prosecution of U.S. Appl. No. 14/237,264. |
An Office Action dated Jan. 30, 2015, which issued during the prosecution of UK Patent Application No. 1413474.6. |
An International Search Report and a Written Opinion both dated May 30, 2016, which issued during the prosecution of Applicant's PCT/IL2016/050125. |
An Office Action dated Sep. 26, 2016, which issued during the prosecution of U.S. Appl. No. 14/763,004. |
An Office Action dated Jan. 18, 2017, which issued during the prosecution of U.S. Appl. No. 14/626,267. |
An Office Action dated Feb. 7, 2017, which issued during the prosecution of U.S. Appl. No. 14/689,608. |
An Office Action dated Feb. 8, 2017, which issued during the prosecution of UK Patent Application No. 1613219.3. |
An Office Action together dated Feb. 10, 2017, which issued during the prosecution of European Patent Application No. 12821522.5. |
An International Search Report and a Written Opinion both dated Oct. 27, 2015, which issued during the prosecution of Applicant's PCT/IL2015/050792. |
European Search Report dated Feb. 18, 2015, which issued during the prosecution of Applicant's European App No. 12821522.5. |
Saturn Project—a novel solution for transcatheter heart valve replacement specifically designed to address clinical therapeutic needs on mitral valve: Dec. 2016. |
Righini presentation EuroPCR. May 2015 (Saturn)—(downloaded from: htlps://www.pcronline.com/Cases-resourcesimages/Resources/Course-videos-slides/2015/Cardiovascularinnovation-pipeline-Mitral-and-tricuspid-valve-interventions). |
An Advisory Action dated Apr. 2, 2018, which issued during the prosecution of U.S. Appl. No. 14/763,004. |
An Office Action dated Jul. 26, 2018, which issued during the prosecution of U.S. Appl. No. 15/872,501. |
An Office Action dated May 4, 2018, which issued during the prosecution of U.S. Appl. No. 15/872,501. |
An Office Action dated Apr. 20, 2018, which issued during the prosecution of U.S. Appl. No. 15/886,517. |
An Office Action dated Aug. 9, 2018, which issued during the prosecution of U.S. Appl. No. 15/899,858. |
An Office Action dated Aug. 9, 2018, which issued during the prosecution of U.S. Appl. No. 15/902,403. |
An Office Action dated Jun. 28, 2018, which issued during the prosecution of Design U.S. Appl. No. 29/635,658. |
An Office Action dated Jun. 28, 2018, which issued during the prosecution of Design U.S. Appl. No. 29/635,661. |
U.S. Appl. No. 62/030,715, filed Jul. 30, 2014. |
An Office Action dated Jun. 6, 2018, which issued during the prosecution of UK Patent Application No. 1720803.4. |
An International Search Report and a Written Opinion both dated Jun. 20, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050024. |
An Office Action dated Jun. 18, 2018, which issued during the prosecution of UK Patent Application No. 1800399.6. |
An Office Action dated Oct. 23, 2017, which issued during the prosecution of U.S. Appl. No. 14/763,004. |
An Office Action dated Dec. 7, 2017, which issued during the prosecution of U.S. Appl. No. 15/213,791. |
Interview Summary dated Feb. 8, 2018, which issued during the prosecution of U.S. Appl. No. 15/213,791. |
An Office Action dated Feb. 7, 2018, which issued during the prosecution of U.S. Appl. No. 15/197,069. |
An Office Action dated Jan. 5, 2018, which issued during the prosecution of U.S. Appl. No. 15/541,783. |
An Office Action dated Feb. 2, 2018, which issued during the prosecution of U.S. Appl. No. 15/329,920. |
An Invitation to pay additional fees dated Jan. 2, 2018, which issued during the prosecution of Applicant's PCT/IL2017/050849. |
An Invitation to pay additional fees dated Sep. 29, 2017, which issued dining the prosecution of Applicant's PCT/IL2017/050873. |
European Search Report dated Jun. 29, 2017, which issued during the prosecution of Applicant's European App No. 11809374.9. |
An Invitation to pay additional fees dated Oct. 11, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050725. |
An Office Action dated Dec. 4, 2018, which issued during the prosecution of U.S. Appl. No. 16/045,059. |
An Office Action together with the English translation dated Nov. 5, 2018 which issued during the prosecution of Chinese Patent Application No. 201680008328.5. |
Notice of Allowance dated Sep. 25, 2018. which issued during the prosecution of U.S. Appl. No. 15/188,507. |
European Search Report dated Sep. 26, 2018 which issued during the prosecution of Applicant's European App No. 18186784.7. |
An Office Action dated Jun. 30, 2015, which issued during the prosecution of U.S. Appl. No. 14/522,987. |
An Office Action dated Sep. 29, 2017, which issued during the prosecution of U.S. Appl. No. 15/197,069. |
Notice of Allowance dated Oct. 30, 2018, which issued during the prosecution of U.S. Appl. No. 15/197,069. |
An Office Action dated Jan. 17, 2018, which issued during the prosecution of U.S. Appl. No. 14/763,004. |
An Office Action dated Mar. 25, 2015, which issued during the prosecution of U.S. Appl. No. 12/840,463. |
An Office Action dated Feb. 25, 2016, which issued during the prosecution of U.S. Appl. No. 14/522,987. |
An Office Action dated Apr. 13, 2016, which issued during the prosecution of U.S. Appl. No. 14/626,267. |
An Office Action dated Aug. 28, 2015, which issued during the prosecution of U.S. Appl. No. 14/237,264. |
An Office Action dated Apr. 21, 2017, which issued during the prosecution of U.S. Appl. No. 15/213,791. |
Maisano (2015) TCR presentation re Cardiovalve. |
Notice of Allowance dated Nov. 19, 2018, which issued during the prosecution of U.S. Appl. No. 15/197,069. |
Notice of Allowance dated May 10, 2016, which issued during the prosecution of U.S. Appl. No. 14/237,258. |
Notice of Allowance dated May 20, 2016, which issued during the prosecution of U.S. Appl. No. 14/237,258. |
Notice of Allowance dated Jul. 6, 2017, which, issued during the prosecution of U.S. Appl. No. 14/689,608. |
Notice of Allowance dated Aug. 18, 2017, which issued during the prosecution of U.S. Appl. No. 14/689,608. |
Notice of Allowance dated May 22, 2017, which issued during the prosecution of U.S. Appl. No. 14/689,608. |
Notice of Allowance dated Feb. 11, 2015, which issued during the prosecution of U.S. Appl. No. 13/033,852. |
Notice of Allowance dated May 5, 2015, which issued during the prosecution of U.S. Appl. No. 12/840,463. |
Notice of Allowance dated Mar. 10, 2015, which issued during the prosecution of U.S. Appl. No. 13/811,308. |
Notice of Allowance dated Mar. 18, 2020, which issued during the prosecution of U.S. Appl. No. 16/284,331. |
An Office Action dated Jan. 14, 2020, which issued during the prosecution of U.S. Appl. No. 16/284,331. |
Notice of Allowance dated May 7, 2020, which issued during the prosecution of U.S. Appl. No. 16/637,166. |
An International Search Report and a Written Opinion both dated Nov. 9, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050869. |
An Office Action dated Jan. 9, 2020, which issued during the prosecution of U.S. Appl. No. 15/600,190. |
An International Search Report and a Written Opinion both dated May 13, 2019, which issued during the prosecution of Applicants PCT/IL2018/051350. |
An International Search Report and a Written Opinion both dated Apr. 25, 2019, which issued during the prosecution of Applicant's PCT/IL2019/050142. |
An International Search Report and a Written Opinion both dated Jan. 25, 2019, which issued during the prosecution of Applicant's PCT/IL2018/051122. |
An International Search Report and a Written Opinion both dated Dec. 5, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050725. |
An International Preliminary Report on Patentability dated Feb. 12, 2019, which issued during the prosecution of Applicant's PCT/IL2017/050873. |
An International Preliminary Report on Patentability dated Feb. 5, 2019, which issued during the prosecution of Applicant's PCT/IL2017/050849. |
An Office Action dated Nov. 26, 2019, which issued during the prosecution of U.S. Appl. No. 16/532,945. |
An Office Action dated Nov. 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/872,501. |
An Office Action dated Mar. 25, 2019, which issued during the prosecution of European Patent Application No. 14710060.6. |
An Office Action dated Oct. 25, 2018, which issued during the prosecution of U.S. Appl. No. 14/763,004. |
An Office Action dated Mar. 4, 2019, which issued during the prosecution of U.S. Appl. No. 14/763,004. |
An Office Action dated Jan. 9, 2019, which issued during the prosecution of U.S. Appl. No. 15/329,920. |
An Office Action dated Jan. 30, 2019, which issued during the prosecution of U.S. Appl. No. 15/872,501. |
An Office Action dated Feb. 5, 2019, which issued during the prosecution of U.S. Appl. No. 15/899,858. |
An Office Action dated May 23, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,659. |
An Office Action dated May 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/691,032. |
An Office Action dated Jun. 25, 2019, which issued during the prosecution of U.S. Appl. No. 15/329,920. |
An Office Action dated Aug. 23, 2019, which issued during the prosecution of U.S. Appl. No. 15/600,190. |
An Office Action dated May 16, 2019, which issued during the prosecution of U.S. Appl. No. 15/433,547. |
An Office Action dated Aug. 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,559. |
An Office Action dated Aug. 16, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,659. |
An Office Action dated Jun. 19, 2019, which issued during the prosecution of U.S. Appl. No. 15/682,789. |
An Office Action dated Jun. 14, 2019, which issued during the prosecution of U.S. Appl. No. 15/703,385. |
An Office Action dated Oct. 4, 2019, which issued during the prosecution of U.S. Appl. No. 16/183,140. |
An Office Action dated Jun. 13, 2019, which issued during the prosecution of U.S. Appl. No. 16/388,038. |
An Office Action dated Sep. 13, 2019, which issued during the prosecution of U.S. Appl. No. 16/460,313. |
Notice of Allowance dated Sep. 10, 2020, which issued during the prosecution of U.S. Appl. No. 15/600,190. |
An International Search Report and a Written Opinion both dated Jun. 24, 2020, which issued daring the prosecution of Applicant's PCT/IL2019/051398. |
Sundermann, Simon H., et al. “Feasibility of the Engager*** aortic transcatheter valve system using a flexible over-the-wire design,” European Journal of Cardio-Thoracic Surgery 42.4 (2012): e48-e52. |
Serruys, P. W., Piazza, N., Cribier, A., Webb, J., Laborde, J. C., & de Jaegere, P. (Eds.). (2009). Transcatheter aortic valve implantation: tips and tricks to avoid failure. CRC Press.—Screenshots from Google Books downloaded from: https://books.google.co.il/books?id=FLzLBQAAQBAJ&lpg=PA198&ots=soqWrDH-y_&dq=%20%22Edwards%20SAPIEN%22&Ir&pg=PA20#v=onepage&q=%22Edwards%20SAPIEN%22&f=false; Downloaded on Jun. 18, 2020. |
Tchetche, D. and Nicolas M. Van Mieghem: “New-generation TAVI devices: description and specifications” EuroIntervention, 2014, No. 10:U90-U100. |
Symetis S.A.: “ACURATE neo™ Aortic Bioprosthesis for Implantation using the ACURATE neo™ TA Transapical Delivery System in Patients with Severe Aortic Stenosis,” Clinical Investigation Plan, Protocol No. 2015-01, Vs. No. 2, 2015:1-76. |
An Office Action dated Jul. 29, 2020, which issued during the prosecution of U.S. Appl. No. 16/269,328. |
Notice of Allowance dated Aug. 26, 2020, which issued during the prosecution of U.S. Appl. No. 16/269,328. |
An Office Action dated Jul. 14, 2020, which issued during the prosecution of U.S. Appl. No. 16/324,339. |
Notice of Allowance dated Aug. 28, 2020, which issued during the prosecution of U.S. Appl. No. 16/324,339. |
An Office Action summarized English translation and Search Report dated Jul. 3, 2020, which issued during the prosecution of Chinese Patent Application No. 201780061210.3. |
An Office Action dated Aug. 7, 2020, which issued during the prosecution of U.S. Appl. No. 15/668,659. |
Notice of Allowance dated Jul. 29, 2020, which issued during the prosecution of U.S. Appl. No. 16/132,937. |
Notice of Allowance dated Apr. 24, 2019, which issued during the prosecution of U.S. Appl. No. 16/045,059. |
Notice of Allowance dated Mar. 12, 2020, which issued during the prosecution of U.S. Appl. No. 16/460,313. |
An International Preliminary Report on Patentability dated Oct. 20, 2020, which issued during the prosecution of Applicant's PCT/IL2019/050142. |
An Office Action dated Oct. 5, 2020, which issued during the prosecution of Canadian Patent Application No. 2,973,940. |
Notice of Allowance dated Nov. 19, 2020, which issued during the prosecution of U.S. Appl. No. 16/318,025. |
An Office Action dated Sep. 24, 2020, which issued during the prosecution of U.S. Appl. No. 16/811,732. |
An Office Action summarized English translation and Search Report dated Nov. 25, 2020, which issued during the prosecution of Chinese Patent Application No. 201910449820.1. |
An Office Action dated Nov. 30, 2020, which issued during the prosecution of U.S. Appl. No. 16/138,129. |
Condado, José Antonio, et al. “Percutaneous edge-to-edge mitral valve repair: 2-year follow-up in the first human case.” Catheterization and cardiovascular interventions 67.2 (2006): 323-325. |
An Office Action dated Dec. 24, 2020, which issued during the prosecution of U.S. Appl. No. 16/144,054. |
An Office Action dated Feb. 2, 2021, which issued during the prosecution of U.S. Appl. No. 16/811,732. |
An Office Action dated Jan. 13, 2021, which issued during the prosecution of European Patent Application No. 15751089.2. |
Maisano, F., et al. “The edge-to-edge technique: a simplified method to correct mitral insufficiency.” European journal of cardio-thoracic surgery 13.3 (1998): 240-246. |
Declaration of Dr. Ivan Vesely, Ph.D. in Support of Petition for Inter Partes Review of U.S. Pat. No. 10,226,341—dated Dec. 17, 2020. |
Petition for Inter Partes Review of U.S. Pat. No. 10,226,341 and Exhibits 1001-1013—dated Dec. 29, 2020. |
An Office Action together with an English summary dated Mar. 3, 2021, which issued during the prosecution of Chinese Patent Application No. 201780047391.4. |
Fucci, C., et al. “Improved results with mitral valve repair using new surgical techniques.” European journal of cardio-thoracic surgery 9.11 (1995): 621-627. |
An Office Action dated Sep. 6, 2018, which issued during the prosecution of U.S. Appl. No. 15/213,791. |
Declaration of Ivan Vesely, Ph.D., in Support of Petition for Inter Partesreview of U.S. Pat. No. 7,563,267—dated May 29, 2019. |
U.S. Appl. No. 60/128,690, filed Apr. 9, 1999. |
Batista, Randas JV, et al. “Partial left ventriculectomy to treat end-stage heart disease.” The Annals of thoracic surgery 64.3 (1997): 634-638. |
Beall Jr, Arthur C., et al. “Clinical experience with a dacron velour-covered teflon-disc mitral-valve prosthesis.” The Annals of thoracic surgery 5.5 (1968): 402-410. |
Kalbacher, D., et al. “1000 MitraClip™ procedures: Lessons learnt from the largest single-centre experience worldwide.” (2019): 3137-3139. |
U.S. Appl. No. 60/613,867, filed Sep. 27, 2004. |
Mitral Valve Academic Research Consortium. “Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles A Consensus Document from the Mitral Valve Academic Research Consortium.” Journal of the American College of Cardiology 66.3 (2015): 278-307. |
Notice of Allowance dated Oct. 3, 2019, which issued during the prosecution of U.S. Appl. No. 15/691,032. |
Notice of Allowance dated Mar. 29, 2017, which issued during the prosecution of U.S. Appl. No. 14/161,921. |
Feldman, Ted, et al. “Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort.” Journal of the American College of Cardiology 54.8 (2009): 686-694. |
Notice of Allowance dated Nov. 21, 2018, which issued during the prosecution of U.S. Appl. No. 15/213,791. |
Notice of Allowance dated Jul. 3, 2019, which issued during the prosecution of U.S. Appl. No. 15/691,032. |
An Office Action dated Jan. 6, 2020, which issued during the prosecution of U.S. Appl. No. 16/660,231. |
Notice of Allowance dated Jan. 13, 2020, which issued during the prosecution of U.S. Appl. No. 15/956,956. |
European Search Report dated Mar. 5, 2020 which issued during the prosecution of Applicant's European App No. 17752184.6. |
An Office Action dated Dec. 31, 2019, which issued during the prosecution of U.S. Appl. No. 16/183,140. |
An Office Action dated Feb. 6, 2020, which issued during the prosecution of U.S. Appl. No. 15/668,659. |
European Search Report dated Mar. 4, 2020 which issued during the prosecution of Applicant's European App No. 16706913.7. |
Urena, Marina, et al. “Transseptal transcatheter mitral valve replacement using balloon-expandable transcatheter heart valves: a step-by-step approach.” JACC: Cardiovascular Interventions 10.19 (2017): 1905-1919. |
An Office Action dated Mar. 29, 2021, which issued during the prosecution of U.S. Appl. No. 16/738,516. |
An Office Action dated Jan. 3, 2020, which issued during the prosecution of U.S. Appl. No. 16/678,355. |
Ando, Tomo, et al. “latrogenic ventricular septal defect following transcatheter aortic valve replacement: a systematic review.” Heart, Lung and Circulation 25.10 (2016): 968-974. |
Poirier, Nancy C., et al. “A novel repair for patients with atrioventricular septal defect requiring reoperation for left atrioventricular valve regurgitation.” European journal of cardio-thoracic surgery 18.1 (2000): 54-61. |
Petitioner's Reply to Patent Owner's Response dated Jan. 5, 2022 in IPR2021-00383. |
Petitioner's Opposition to Patent Owner's Contingent Motion to Amend dated Jan. 5, 2022 in IPR2021-00383. |
Decision Granting Institution of Inter Partes Review dated Dec. 10, 2021 in IPR2021-01051 (42 pages total). |
Notice of Allowance dated Dec. 7, 2021 in U.S. Appl. No. 17/394,807. |
Office Action dated Nov. 4, 2021 in U.S. Appl. No. 17/366,711. |
Extended European Search Report dated Oct. 11, 2021 in European Application No. 21176010.3. |
Fann et al., “Beating Heart Catheter-Based Edge-to-Edge Mitral Valve Procedure in a Porcine Model”, Circulation, 2004, vol. 110, pp. 988-993, Cardiovalve Exhibit 2006 (6 pages total). |
Feldman et al., “Percutaneous Mitral Leaflet Repair: MitralClip Therapy for Mitral Regurgitation”, Informa Healthcare, 2012, CRC Press, pp. 31-44, Cardiovalve Exhibit 2009 (8 pages total). |
Feldman et al., “Percutaneous Mitral Valve Repair Using the Edge-to-Edge Technique”, Journal of the American College of Cardiology, 2005, vol. 46, No. 11, pp. 2134-2140 (7 pages total). |
IPR2021-00383 “Patent Owner's Contingent Motion to Amend”, dated Oct. 13, 2021 (35 pages total). |
IPR2021-00383 “Patent Owner's Response”, dated Oct. 13, 2021 (75 pages total). |
Maisano et al., “The Evolution From Surgery to Percutaneous Mitral Valve Interventions”, Journal of the American College of Cardiology, 2011, vol. 58, No. 21, pp. 2174-2182 (9 pages total). |
Notice of Allowance dated Sep. 15, 2021 in U.S. Appl. No. 16/135,599. |
Office Action dated Oct. 14, 2021 in U.S. Appl. No. 16/680,739. |
Office Action dated Oct. 21, 2021 in U.S. Appl. No. 17/306,231. |
Office Action dated Oct. 21, 2021 in U.S. Appl. No. 17/335,845. |
Office Action dated Sep. 9, 2021 in U.S. Appl. No. 16/768,909. |
Second Declaration of Dr. Michael Sacks, Oct. 13, 2021, IPR2021-00383, U.S. Pat. No. 10,226,341, United States Patent and Trademark Office, Before the Patent Trial and Appeal Board, Cardiovalve Exhibit 2014 (28 pages total). |
Transcript of Dr. Vesely, Sep. 22, 2021, Case No. IPR2021-00383, U.S. Pat. No. 10,226,341 United States Patent and Trademark Office Before the Patent Trial and Appeal Board, Cardiovalve Exhibit 2010 (170 pages total). |
IPR2021-00383 “Petitioners' Authorized Reply to Patent Owner's Preliminary Response”, dated May 27, 2021, 9 pages. |
Exhibit 1014 , “Transcript of proceedings” held May 20, 2021, 15 pages. |
Exhibit 1015, “Facilitate”, Meriam-Webster.com, https://www.merriamwebster.com/dictionary/facilitate, retrieved May 26, 2021, 5 pages. |
IPR2021-00383, “Patent Owner's Authorized Surreply to Petitioner's Reply to Patent Owner's Preliminary Response”, dated Jun. 4, 2021, 8 pages. |
IPR2021-00383, “Institution decision” dated Jul. 20, 2021, 51 pages. |
An extended European search report dated Jun. 10, 2021 in application No. 21157988.3. |
International Search Report and Written Opinion dated Jul. 12, 2021 from the International Searching Authority in International Application No. PCT/IL2021/050132. |
An Office Action dated May 4, 2021, which issued during the prosecution of U.S. Appl. No. 16/636,204. |
Notice of Allowance dated May 17, 2021, which issued during the prosecution of U.S. Appl. No. 16/138,129. |
Petition for Inter Partes Review of U.S. Pat. No. 10,702,385—dated Jun. 4, 2021. |
Declaration of Ivan Vesely, Ph.D. In Support of Petition for Inter Partes Review of U.S. Pat. No. 10,702,385—dated Jun. 4, 2021. |
An English summary of an Official Action dated Mar. 29, 2021, which issued during the prosecution of Chinese Patent Application No. 201780061210.3. |
An International Search Report and a Written Opinion both dated Jan. 28, 2020, which issued during the prosecution of Applicant's PCT/IL2019/051031. |
An International Preliminary Report on Patentability dated Mar. 9, 2021, which issued during the prosecution of Applicant's PCT/IL2019/051031. |
An Office Action dated May 12, 2021, which issued during the prosecution of Canadian Patent Application No. 2,973,940. |
Notice of Allowance dated Jun. 4, 2021, which issued during the prosecution of U.S. Appl. No. 16/802,353. |
An Office Action dated Aug. 1, 2022, which issued during the prosecution of European Patent Application No. 18826823.9. |
An Office Action dated Aug. 5, 2022, which issued during the prosecution of U.S. Appl. No. 16/760,147. |
An Office Action dated Jul. 20, 2022, which issued during the prosecution of U.S. Appl. No. 17/101,787. |
An Office Action dated Jul. 27, 2022, which issued during the prosecution of U.S. Appl. No. 16/881,350. |
An Office Action dated Sep. 16, 2022, which issued during the prosecution of U.S. Appl. No. 16/135,466. |
An Office Action dated Sep. 21, 2022, which issued during the prosecution of U.S. Appl. No. 16/776,581. |
An Office Action dated Sep. 8, 2022, which issued during the prosecution of U.S. Appl. No. 16/896,858. |
European Search Report dated Sep. 6, 2022 which issued during the prosecution of Applicant's European App No. 22161862.2. |
IPR2021-01051 Patent Owner's Sur-Reply To Petitioners' Reply To Preliminary Guidance dated Aug. 23, 2022. |
IPR2021-01051 Petitioners' Reply to Preliminary Guidance dated Aug. 2, 2022. |
An International Search Report and a Written Opinion both dated May 3, 2022, which issued during the prosecution of Applicant's PCT/IL2021/051433. |
An Office Action dated Jul. 8, 2022, which issued during the prosecution of U.S. Appl. No. 16/144,054. |
An Office Action dated Jun. 28, 2022, which issued during the prosecution of U.S. Appl. No. 16/135,969. |
An Office Action together with an English Summary dated May 7, 2022 which issued during the prosecution of Chinese Patent Application No. 201880058940.2. |
Ex Parte Quayle dated May 2, 2022, which issued during the prosecution of U.S. Appl. No. 16/879,952. |
IPR2021-00383 Final Written Decision dated Jul. 18, 2022. |
IPR2021-01051 Preliminary Guidance Patent Owner's Motion to Amend dated Jun. 24, 2022. |
Notice of Allowance dated May 4, 2022, which issued during the prosecution of U.S. Appl. No. 16/680,739. |
An Office Action dated Jan. 26, 2022, which issued during the prosecution of U.S. Appl. No. 16/888,210. |
Notice of Allowance dated Jan. 31, 2022, which issued during the prosecution of U.S. Appl. No. 17/479,418. |
An Office Action dated Mar. 18, 2022, which issued during the prosecution of U.S. Appl. No. 16/746,489. |
Notice of Allowance dated Mar. 22, 2022, which issued during the prosecution of U.S. Appl. No. 17/366,711. |
Notice of Allowance dated Mar. 4, 2022, which issued during the prosecution of U.S. Appl. No. 16/768,909. |
An Office Action dated Dec. 9, 2021, which issued during the prosecution of U.S. Appl. No. 16/135,969. |
An Office Action dated Jan. 24, 2022, which issued during the prosecution of U.S. Appl. No. 16/135,466. |
An Office Action dated Apr. 11, 2022, which issued during the prosecution of U.S. Appl. No. 17/473,472. |
IPR2021-00383 Preliminary Guidance dated Jan. 31, 2022. |
Notice of Allowance dated Dec. 29, 2021 in U.S. Appl. No. 17/210,183. |
An invitation to pay additional fees dated May 19, 2021, which issued during the prosecution of Applicant's PCT/IL2021/050132. |
An Office Action dated Aug. 18, 2021, which issued during the prosecution of U.S. Appl. No. 17/210,183. |
Edwards reply to Preliminary Guidance filed Aug. 2, 2022 in IPR2021-01051 (17 pages total). |
Cardiovalve's Sur-reply to EDW's Reply to Preliminary Guidance dated Aug. 23, 2022 in IPR2021-01051 (10 pages total). |
An Office Action dated Sep. 29, 2022, which issued during the prosecution of U.S. Appl. No. 17/010,886. |
An Office Action dated Sep. 29, 2022, which issued during the prosecution of U.S. Appl. No. 16/656,790. |
IPR2021-01051 final written decision dated Dec. 6, 2022. |
Number | Date | Country | |
---|---|---|---|
20230346550 A1 | Nov 2023 | US |
Number | Date | Country | |
---|---|---|---|
61588892 | Jan 2012 | US | |
61537276 | Sep 2011 | US | |
61555160 | Nov 2011 | US | |
61525281 | Aug 2011 | US | |
61515372 | Aug 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17982897 | Nov 2022 | US |
Child | 18218419 | US | |
Parent | 16888210 | May 2020 | US |
Child | 17982897 | US | |
Parent | 16284331 | Feb 2019 | US |
Child | 16888210 | US | |
Parent | 15197069 | Jun 2016 | US |
Child | 16284331 | US | |
Parent | 14237258 | US | |
Child | 15197069 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13412814 | Mar 2012 | US |
Child | 14237258 | US |